RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

(A Govt. of Rajasthan Undertaking)

Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India Tel No: 0141-2228066, 2228064, E-mail: rmsc@nic.in, edprocurement@gmail.com

E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES (Two year Rate Contract ending on 31.03.2018)



LAST DATE OF SUBMISSION OF ONLINE BIDS:- 04.02.2016

मुख्यमंत्री निःशुल्क दवा योजना



Ministry of Health & Family Welfare Government of Rajasthan RMSCL

"Mukhyamantri Nishulak DavaYojana"

Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India Phone No: 0141-2228066, 2228064 Fax No. 0141-2228065 Website: www.rmsc.nic.in

CIN:U24232RJ2011SGC035067 E_mail: edprocurement@gmail.com, and rmsc@nic.in

Ref. No.: F.02(169)/RMSC/PROCUREMENT/DRUG/NIB-01/2015/01 Dated: 01.01.2016

Notice Inviting E-Bids

E-bids are invited upto 1.30 PM of 04.02.2016 for Rate Contract cum Supply and Empanelment of drug and medicines. Details of NIB may be seen in the Bidding Documents at our office or at the website of State Public procurement Portal http://sppp.raj.nic.in, www.dipronline.org, http://eproc.rajasthan.gov.in., www.rmsc.nic.in and may be downloaded from there.

Note:- If any amendment is carried out in the tender specifications and terms & conditions following pre-bid meeting, the same will be uploaded on the Departmental website www.rmsc.nic.in, sppp.raj.nic.in and https:// eproc.rajasthan.gov.in. In case any inconvenience is felt, please contact on telephone number i.e. 0141- 2228064

Executive Director (Procurement)
RMSCL

RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES

(Two year Rate Contract ending on 31.03.2018)

Bid Reference : F.02(169)/RMSC/PROCUREMENT/

:

DRUG/ NIB-01/2015/01 Dated: 01.01.2016

Pre- bid conference : **08.01.2016 at 11.30 AM**

(RMSC meeting Hall)

Date and time for downloading

bid document0

04.01.2016 from 03.00 PM

Last date and time of submission

of online bids and e-deposit

04.02.2016 at 1.30 PM

Date and time of opening of

Online technical bids

04.02.2016 at 2.30PM

Cost of the Bid Document : Rs. 2000/-

For SSI Unit of Rajasthan : Rs. 1000/-

RISL Processing Fees : **Rs. 1000/-**

Empanelment Fee : Rs. 5000/-

(If applying for Empanelment also)

<u>INDEX</u>

| S.NO | PARTICULARS | | | | | |
|------|---|--|--|--|--|--|
| | General instruction for bidders | | | | | |
| 1. | Last date for receipt of bids, bid document fees, Bid Security Deposit, RISL processing | | | | | |
| | fees and empanelment fees | | | | | |
| 2. | Eligibility criteria | | | | | |
| 3. | Purchase preference | | | | | |
| 4. | General conditions | | | | | |
| 5. | Technical bid | | | | | |
| 6. | Price bid | | | | | |
| 7. | Opening of technical and financial evaluation | | | | | |
| 8. | Bid security deposit | | | | | |
| 9. | Other conditions | | | | | |
| 10. | Acceptance of bid | | | | | |
| 11. | Security deposit(performance guarantee) | | | | | |
| 12. | Agreement | | | | | |
| 13. | Supply conditions | | | | | |
| 14. | Logograms / markings | | | | | |
| 15. | Packing | | | | | |
| 16. | Quality testing | | | | | |
| 17. | Payment provisions | | | | | |
| 18. | Deduction in payments: | | | | | |
| 19. | Quality control deduction & other penalties: | | | | | |
| 20. | Empanelment of firms | | | | | |
| 21. | Saving clause | | | | | |
| 22. | Jurisdiction | | | | | |
| 23. | Correction of arithmetic errors: | | | | | |
| 24. | Procuring entity's right to vary quantity: | | | | | |
| 25. | Dividing quantities among more than one bidder at (in case of procurement of goods): | | | | | |
| 26. | Grievance redressal during procurement process: | | | | | |
| 27. | Compliance with the code of integrity and no conflict of interest: | | | | | |
| 28. | Fall Clause | | | | | |
| 29. | Annexure-I Bank Challan | | | | | |
| 30. | Annexure -II Format of Affidavit | | | | | |
| 31. | Annexure -III Annual Turn Over Statement | | | | | |
| 32. | Annexure -IV Agreement | | | | | |
| 33. | Annexure - V Check List | | | | | |
| 34. | Annexure - VI Check List of Details Regarding Products Quoted | | | | | |
| 35. | Annexure - VII Declaration & Undertaking | | | | | |
| 36. | Annexure - VIII List of Drugs With Specifications | | | | | |
| 37. | Annexure - IX Guidelines for Blacklisting/Debarring of Product or Supplier/Company | | | | | |
| 38. | Annexure - X Memorandum of Appeal Under The Rajasthan Transparency In Public | | | | | |
| 20 | Procurement Act, 2012 | | | | | |
| 39. | Annexure -XI Undertaking For Empanelment | | | | | |
| 40. | Annexure -XII Supplier Consolidated Invoice | | | | | |
| 41. | Annexure -XIII Analytical Report Regarding Quality | | | | | |
| 42. | Annexure -XIV Security form (Bank guarantee) | | | | | |
| 43. | Annexure -XV Performance Statement | | | | | |

GENERAL INSTRUCTIONS FOR BIDDERS

The bidders are instructed to read the complete bid document carefully. The following points may be noted so that mistakes/lapses/shortcomings during Bid submission may be avoided.

- 1. It is expected from all bidders that they will ensure that documents to be used in bid set will be given to a reliable person only, and that only a fully reliable person shall be authorized for DSC. So that the confidentiality of your bid/rates is maintained upto bid opening & that your documents are not put to any misuse.
- 2. Complaints lodged in RMSC should bear signature, name, Id proof and mobile number of the complainant. This is important as RMSC has received many complaints in the past on letter heads of certain companies who later on denied to have made the complaint upon their verification. Rather, a few companies have asked RMSC to take action against those persons who have fraudulently made use of their letter heads. Therefore, unauthenticated complaints may not be acted upon.
- 3. In case you are given any assurance of any favour in RMSC, by anybody or if you are directly or indirectly threatened or intimidated of harming your bidding & subsequent work in RMSC, please inform immediately about the same to MD, RMSC or ED(Proc.) RMSC. It would be better if evidence of such unfair activity of such person is produced so that action can be taken against such person / institution and their details can be put on the website.
- 4. It is advisable for you to authorize only those persons for RMSC tender who are employed in your company on salary basis.
- 5. If any firm, etc intends to lodge a complaint against a bidder with regard to bid (bid Condition), it may do so within 21 days of opening of technical bid, in the office of RMSC. After the stipulated period, it will not be possible to act upon the complaint.
- 6. The turnover should be as per bid conditions. Do not submit Bid if the turnover of the firm is less.
- 7. Quote only for the products for which your Product Permission meets the Bid specifications. Do not quote if it differs with regard to any parameter.
- 8. Quote rate in BOQ for the packing exactly given in annexure VIII. For example

- If the packing unit is given for 10x10 tablets / capsule, the rate should be quoted for 10x10 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
- If the packing unit is given for 10x10x1 tablets / capsule, the rate should be quoted for 10x10 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
- If the packing unit is given for 10x14 tablets / capsule, the rate should be quoted for 10x14 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
- If the packing unit is given for 2 ml ampoule (25 ampoules), the rate should be for 25 ampoules and not for 1 ampoule or 10 ampoules etc.
- If the packing unit is given for 2 ml ampoule (10 ampoules), the rate should be for 10 ampoules and not for 1 ampoule etc.
- 9. Highlight the quoted items in the documents like Product Permission and Market Standing Certificate, and also mark the item code no. at appropriate place in the documents.
- 10. The uploaded product permission and other documents should be clearly legible. Date of issue of the documents should be clearly legible.
- 11. Upload the Bids on the e-portal well in advance so that failure in uploading can be avoided and no desired document remains un-uploaded.
- 12. In case there is any suggestion regarding Bid conditions/specifications/shelf life, strength, packing/turn over etc. The suggestions should be submitted/sent/E Mailed one/two days earlier from the date of pre bid meeting so that the representation of the bidders may be well processed and decision could be taken well in time.
- 13. If there is any query regarding Terms and condition in Bid document, you may contact
 - Sh. Deepak Sharma, Sr. Manager (Drugs) Mob. No. 08875298700
 - Sh. K.K. Moolchandani, Manager (Procurement) Mob. No. 09460764250

RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES

(Two year Rate Contract ending on 31.03.2018)

Rajasthan Medical Services Corporation Ltd., (hereinafter referred to as Bids Inviting Authority unless the context otherwise requires) invites E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES.

1. LAST DATE FOR RECEIPT OF BIDS, BID DOCUMENT FEES, BID SECURITY DEPOSIT, RISL PROCESSING FEES AND EMPANELMENT FEES

- (a) E-Bids [in two separate bids (Technical bid & Price Bid)] will be received till 04.02.2016 at 1.30 PM by the Rajasthan Medical Services Corporation Ltd, for the rate contract cum supply and empanelment for supply of drugs and medicines. (Two year Rate Contract ending on 31.03.2018)
- (b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity period for an additional specified period of time. The Bidder may refuse extension of bid validity, and in such a case its Bid security deposit shall not be forfeited.
- (c) The e-Bids will be received on e-procurement web-portal of Govt. of Rajasthan. Every Bidder will be required to pay the following fees:
 - Bid form fee Rs. 2000.00 (Rs. 1000.00 for SSI Units of Rajasthan) for downloading from the website.
 - Bid Security Deposit as applicable in Bid condition no. 8.
 - Processing fee of Rs.1000.00 of R.I.S.L.

These fees are to be paid through three separate prescribed challans (*format enclosed in Annexure-I*) in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country upto 03.02.2016 or through D.D. / bankers cheque in favour of M.D. RMSCL (Bid document

fees and Bid security), M.D. RISL (Bid processing fees) physically in the office of RMSC by 1.30 PM on 04.02.2016 Alternatively bidder may also deposit Bid document fees, Bid security and RISL processing fees by way of e-deposit, through Internet Banking by accessing RMSC website rmsc.nic.in clicking e-deposit icon following the laid down steps; Rs.25 plus applicable service tax will be the per transaction charge to be debited in respective depositor's account after successful e-deposit. Supplier should enclose the generated receipt. The bidders shall submit/upload scanned copy of all the challans/DD/ e – deposit generated receipt in Technical Bid. Bids will be opened only after ensuring receipt of Bid document fees along with processing fees and Bid Security Deposit. In the absence of Bid document fees and processing fees and Bid Security Deposit the Bids will be rejected and will not be opened.

Note:- (I) While the Bid uploading it would be asked on e procurement website about Bid Security, whether it is Rs. 2.00 lacs or Rs. 5.00 lacs, the bidder may mention any option for the purpose of Bid uploading but has to submit required Bid Security as specified in clause no 8.

Note:- (II) There is no option of online payment of tender fee, processing fee, bid security etc. on e-procurement portal. Therefore the bidder is advised to submit the required fees and bid security through internet banking only by accessing RMSC website www.rmsc.nic.in.

Click on offline mode (either DD or BC) on e procurement portal for the purpose of bid uploading only.

(d) Those who wish to apply for Empanelment as supplier for Drugs and Medicines are required to deposit separately an Empanelment Fee of Rs 5000 (Five Thousand rupees only) in the form of DD (in favour of MD, RMSCL)/challan/e-deposit before due time and date of bid submission. Please see clause 20 and Annexure-XI in this regard.

Note:-The bidders who have already paid empanelment fees in previous bid need not to submit the empanelment fee for the items being quoted in this bid. However the required annexure must be submitted.

2. ELIGIBILITY CRITERIA

- (a) Bidder shall be a manufacturer having valid manufacturing license or direct importer holding valid import license. Distributors/ Suppliers / Agents are not eligible to participate in the Bids.
- (b) Average Annual turnover (for drugs and medicines including Surgical and sutures Business) in the last three financial years (2011-12, 2012-13 and 2013-14 or 2012-13, 2013-14 and 2014-15) shall not be less than Rs. 20 Crores. For SSI units of Rajasthan, the average annual turnover in the last three financial years (2011-12, 2012-13 and 2013-14 or 2012-13, 2013-14 and 2014-15) should not be less than Rs. 2 Crores. For drug items falling in the category of Disinfectants & Antiseptics, Eye preparations and Ear drops etc (item code-215A, 241, 244, 246, 247, 248, 252, 319, 320, 324, 326, 421, 423, 424, 449, 484, 485, 571, 586, 587, 589, 612, 614) and for item code 60, 152, 212, 229, 316, 347, 399, 457, 522, 539, 551, 567, 602, 606, 609, 625, 628 the bidders firms average annual turnover of last three financial years should not be less than Rs. 2 Cr and for item code 285, 616, 617, 618 the bidders firms average annual turnover of last three financial years should not be less than Rs. 10 Cr.

Explanatory Note:-

- 1) The merger / amalgamation / transfer of business / transfer of assets / share in sister concern (if there is no separate legal entity of sister concern) / share in joint venture etc. of a firm affect the bid condition relating to 'Turnover' in preceding years. The eligibility of a bidder in this regard shall be ascertained by the Purchase Committee on the basis of the above stated agreement / BOD resolution / CA certificate or any other document(s) annexed with the tender documents and the decision of Purchase Committee shall be final.
- 2) The amount shown as Turnover in the tender should be the amount as per VAT Act / other Acts and necessary documents / certificates shall be annexed with tender documents and accordingly eligibility of a bidder in this regard shall be ascertained by the Purchase Committee.
- (c) Bidder should have at least 3 years market standing as a manufacturer for the items quoted in the bid, on the date of bid opening. The bidder should also have manufactured at least 3 commercial batches of the quoted drug every year in

the last 3 consecutive years (Annexure XV). In the case of imported products, the product should have minimum 3 years standing in the market. The importer should have at least 3 years standing as manufacturer/ importer of drugs in general. Imported drugs shall be accepted in brand name also.

Explanatory Note:

The merger / amalgamation / transfer of business / transfer of assets / share in sister concern (if there is no separate legal entity of sister concern) / share in joint venture etc. of a firm affect the bid condition relating to 'Past Performance' / 'Market Standing Certificate' in preceding years. The eligibility of a bidder in this regard shall be ascertained by the Purchase Committee on the basis of the above stated agreement / BOD resolution / CA certificate or any other document(s) / certificates which shall be annexed with the tender documents.

- (d) Bidder should have permission to manufacture the item /drug quoted as per specification given in the Bid, from the competent authority. Product permission of *brands* shall be accepted in the Bid submitted, but the Bidder has to submit the product permission in generic names at the time of signing of the agreement/before supply.
- (e) Bid should not be submitted for the product/products for which the concern/company stands blacklisted/banned/debarred either by Bid inviting Authority or Govt. of Rajasthan or its departments on any ground.
 - The Bid should not be submitted for those products also for which the concern/company stands blacklisted/banned/debarred by any other State/Central Govt. or it's any agencies (central Drugs procurement agencies) on the ground of conviction by court of law or the products being found spurious or adulterated.
- (f) The concern/company/firm which stands blacklisted/banned/debarred on any ground either by Bid Inviting Authority (RMSC) or Govt. of Rajasthan or its departments on the date of bid submission, shall not be eligible to participate in the Bid.

The concern/company/firm which stands blacklisted/banned/debarred on the ground of conviction by court of law or the products being found spurious or adulterated by any other State /Central Government or it's any agencies (central Drugs procurement agencies) shall also not be eligible to participate in the Bid. For Specific cases regarding other quality issues the purchase committee of RMSC may decide the case on merit basis.

- (g) If any product/products of a company/firm have been declared as not of standard quality, as per Drugs & Cosmetics Act during last 2 years anywhere, such concern/company/firm shall not be eligible to participate in Bid for such product/products. If any company/firm is found to have any such product quoted in the Bid, the product shall be blacklisted for 2 years and a penalty equivalent to Bid Security Deposit shall also be levied. [Penalty should be minimum and maximum as per bid security given in clause 8] In such situation, the bid will be considered further only if the amount of penalty is deposited before the completion of technical evaluation.
- (h) The concern/firm/company whose product has been declared as of spurious or adulterated quality and any criminal case is filed and pending in any court shall not be eligible to participate for that particular product, in the Bid. Similarly convicted firm/company shall also not be eligible to participate in the Bid.
- (i) If a company has two or more separate manufacturing units at different sites/states, the company will be allowed to submit only one Bid for all units but necessary document regarding separate manufacturing units will be submitted as a separate set with the same Bid. But a bidder will be allowed to submit only one offer for one product.

3. PURCHASE PREFERENCE

- i. Purchase preference admissible to the PSUs of the state of Rajasthan and to the SSI of the state of Rajasthan, together shall not exceed 25% (10% for PSUs and 15% of SSI units or 25% preference may be given to PSU if there is no SSI unit to avail this benefit). However these units will be required to participate in Bidding process and match L-1 price.
- ii. Comparison of rates of firms outside and those in Rajasthan:-

While tabulating the Bids of those firms which are not entitled to price preference, the element of Rajasthan VAT shall be excluded from the rates quoted by the firms of Rajasthan and the element of CST shall be included in the rates quoted by the firms of outside Rajasthan. In such case if the price of any commodity being offered for sale by firms in Rajasthan is the same or lower (excluding Rajasthan VAT) than the price of firm outside Rajasthan (including element of CST), the commodity shall be purchased from the firm in Rajasthan.

- iii. VAT on drugs and medicines are exempted in Rajasthan. RMSCL will issue necessary exempted certificate.
- iv. RMSC will also issue "C-certificate" in case of interstate supply. Therefore concessional CST should be charged

4. GENERAL CONDITIONS

- i. At any time prior to the date of submission of Bid, Bid Inviting Authority may, for any reason, whether on his own initiatives or in response to a clarification requested by a prospective Bidder, modify the condition in Bid documents by amendment. In order to provide reasonable time to take the amendment into account in preparing their bid, Bid Inviting Authority may at his discretion, extended the date and time for submission of Bids.
- ii. Interested eligible Bidders may obtain further information in this regard from the office of the Bid Inviting Authority.
- iii. In case any document submitted by the bidder or his authorized representative is found to be forged, false or fabricated, the bid will be rejected and Bid Security Deposit /Performance Security will be forfeited. Bidder/his representative may also be blacklisted/banned/debarred. Report with police station may also be filed against such bidder/his representative.

5. TECHNICAL BID

The Bidder should furnish the following in technical bid:-

(a) Bidders are allowed the option to quote for anyone item or more items as mentioned in bid (list of medicines proposed to be purchased at Annexure-VIII). The amount of Bid Security Deposit will remain @ Rs. 20,000/- per item of drug quoted subject to minimum of Rs.2.00 lacs and maximum of Rs.5.00 lacs.

- (b) The bidders shall submit/upload scanned copy of all the challans, D.D./ BC/ e-deposit generated receipt in Technical Bid deposited for Bid document fees, RISL processing fee and Bid security. The required Bid Security Deposit / Bid document fees/ RISL fee may be in form of physical D.D./ BC along with letter. D.D. / bankers cheque shall be in favour of M.D. RMSCL (bid document fees and Bid Security Deposit), MD, RISL (bid processing fees).
- (c) Those who wish to apply for Empanelment as supplier for Drugs and Medicines are required to deposit separately an Empanelment Fee of Rs 5000 (Five Thousand rupees only) in the form of DD /challan/e-deposit in favour of MD, RMSCL before due time and date of bid submission.
- (d) Documentary evidence for the constitution of the company/Firm such as Memorandum and Articles of Association, Partnership Deed etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director/Partners/Proprietor.
- (e) The Bidder should furnish attested copy of the valid License for the product duly approved by the Licensing authority for each and every product quoted as per specification in the Bid. The license must have been duly renewed/valid up to date and the items quoted shall be clearly highlighted (*Bid item codes marked against each item*) in the license.
- (f) Attested photocopy of the valid import license in Form 10 with Form 41 (as per Rule 122A of Drugs and Cosmetics Act), if the product is imported. The license must have been renewed /valid up to date. A copy of a valid license for the sale of Drugs imported by the firms issued by the licensing authority shall be enclosed.
- (g) The instruments such as power of attorney, resolution of board etc., authorizing an officer of the Bidder should be enclosed.
- (h) Authorization/nominating a responsible person of the Bidder to transact the business with the Bid Inviting Authority with photograph and signature in Annexure VII.
- (i) Bidder should have at least 3 years market standing as a manufacturer for the items quoted in the bid.

For imported items, the quoted item should have 3 years market standing, for which bills of entry, sale invoices, etc should be submitted to establish the claim. The importing firm should have 3 years standing as importer / manufacturer of medicines in general. The manufacturer may submit his licence or MARKET STANDING CERTIFICATE to establish 3 years standing; The importer firm may submit Bills of entry, etc of same or other Surgical /Drugs to establish the market standing of the firm. The bidder shall submit valid import license for direct import of the quoted item.

- (j) Market Standing Certificate issued by the Licensing Authority / competent authorities as a Manufacturer for the product for last 3 years (Certificate should be enclosed with list of items) should be enclosed. Items quoted should be highlighted in the market standing certificate. For imported items, the quoted item should have 3 years market standing, for which bills of entry, sale invoices, etc should be submitted to establish the claim. The importing firm should have 3 years standing as importer / manufacturer of medicines in general. The manufacturer may submit his licence or MARKET STANDING CERTIFICATE to establish 3 years standing; the importer firm may submit Bills of entry, etc of same or other drugs to establish 3 years for importing the items and to establish the market standing of the firm. The MSC should not have been issued by competent authority more than 2 years old as on the last date of **bid submission.** The bidder shall submit valid import licence for import of the quoted item. The market standing of products containing Paracetamol 500 mg shall be accepted in tablet combination where Paracetamol 325 mg is specified. However, for all above, the firm has to submit with bid, the product permission (from the Licensing Authority) as per bid specifications of the RMSC formula.
- (k) Non-conviction Certificate issued by the Drugs Controller of the State. It should be recent and not more than one year old.
- (l) WHO-GMP (WHO Good manufacturing practices Certificate)
 Certificate issued by the Licensing Authority. The WHO-GMP

certificate must not be older than one year from the due date of Bid submission in the case where validity is not mentioned in the certificate. *The WHO-GMP certificate of all the manufacturing plants, of which products have been quoted, should be submitted.* The Bidder shall also furnish an undertaking in the format given in Annexure-VII point no.8 declaring that the Bidder complies with the requirements of WHO-GMP. The Importer should produce WHO- GMP /COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US- FDA approval, etc. In the case of imported drugs, labels and product literature of all quoted products must be submitted.

(m) Annual turnover statement for 3 years i.e., 2011-12, 2012-13 and 2013-14 or 2012-13, 2013-14 and 2014-15 in the format given in Annexure-III certified by the practicing Chartered Accountant.

Explanatory Note:-

- 1) The merger / amalgamation / transfer of business / transfer of assets / share in sister concern (if there is no separate legal entity of sister concern) / share in joint venture etc. of a firm affect the bid condition relating to 'Turnover' in preceding years. The eligibility of a bidder in this regard shall be ascertained by the Purchase Committee on the basis of the above stated agreement / BOD resolution / CA certificate or any other document(s) annexed with the tender documents and the decision of Purchase Committee shall be final.
- 2) The amount shown as Turnover in the tender should be the amount as per VAT Act / other Acts and necessary documents / certificates shall be annexed with tender documents and accordingly eligibility of a bidder in this regard shall be ascertained by the Purchase Committee.
 - (n) Copies of the Balance Sheet and Profit and Loss Account for three years i.e. 2011-12, 2012-13 and 2013-14 or 2012-13, 2013-14 and 2014-15 duly certified by the practicing Chartered Accountant.
 - (o) VAT/Sales Tax Clearance certificate (copies of latest challans), as on *31.06.2015*.
 - (p) Registration with Excise Department, Govt. of India. The industries situated in excise free zones will be exempted from the registration provided they produce the copy of appropriate notification.

- (q) Undertaking (as in Annexure-VII) for embossment of logo on labels of bottles, etc as the case may be, as per conditions specified at Clause 14 herein.
- (r) Undertaking that the manufacturer has not been blacklisted, the product has not been declared as not of standard quality during last two years, it's manufacturing capacity and other details required on a format mentioned at Annexure-VII.
- (s) Details of technical personnel employed in the manufacture and testing of drugs (Employee Name, Qualification, and Experience) as enclosed in license.
- (t) List of items quoted to be shown in the **Annexure-VII** point number 6
- (u) A Checklist (Annexure-V) for the list of documents enclosed with their page number. The documents should be serially arranged as per Annexure-V. Every bidder will also be required to submit details of product permission of the quoted item and the desired market standing, in Annexure-VI
- (v) An undertaking that the bidder complies with all the terms, conditions, amendments (if any) of bid document to be submitted in **Annexure-VII** point no.11.
- (w) A declaration under Section 7 of Rajasthan Transparency in Public Procurement Act, 2012 in Annexure-VII point no. 13
- (x) All copies submitted should be self attested.
- (y) An undertaking in Annexure-XI that the bidder whishes to get empanelled as supplier for the quoted items and has submitted the necessary fee for the same. (This is only for those who apply for empanelment also). The bidders who have already paid empanelment fees in previous bid need not to submit the empanelment fee for the items being quoted in this bid. However the required annexure must be submitted.
- (z) A copy of PAN issued by Income Tax Department.

Note:- 1. Clarification regarding submission of documents

It is found that some of the documents are sometimes not valid on the exact date of bid opening; the firm has submitted slightly older documents in the bid as it has not been able to get the new/renewed certificate issued from the concerned department till bid submission. Documents such as Non conviction certificate, WHO-GMP certificate & MSC shall be accepted if they have been issued after bid submission but submitted to Tendering authority when asked to do so in the form of clarification/short fall documents. But such documents shall be considered only if it is proved that the competence as certified by the competent authority regarding the required documents existed with the bidder on the date of submission of bid.

Note:- 2. Some additional relaxation for the following items

| S. | Code | Name of Item With | Relaxation in condition |
|----|------|--|--|
| No | No. | Specification | |
| 1. | 368 | Cough Syrup Each 5ml contains Chloropheniramine Maleate IP 3mg Ammonium Chloride 130mg, Sodium Citrate 65 mg, Menthol 0.5 mg, Syrup Q.S. | Market standing of the firm's formulation with similar active ingredients (quantities may differ) will be accepted. However, the firm has to submit with tender, the product permission (from the Licensing Authority) as per tender specifications of the RMSC formula. |
| 2. | 522 | Pyrimethamine and Sulphadoxine Tablets IP (Pyrimethamine 37.5 mg and Sulphadoxine 750 mg) | Market Standing Certificate and Performance Statement of two year acceptable. |
| 3. | 587 | Clotrimazole 1% with lignocaine 1% Ear Drops | Market Standing Certificate and Performance Statement of two year acceptable. |
| 4. | 609 | Chlorzoxazone Tablets 250 mg | Market Standing Certificate and Performance Statement of two year acceptable. |
| 5. | 628 | Riboflavin Tablets IP 5 mg | Market Standing Certificate and Performance Statement of two year acceptable. |

6. PRICE BID -

The price bid will also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). BOQ template must not be modified/ replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bidder is liable to be rejected for this bid. Bidders are allowed to enter the bidder name and values only. The bidder should quote rate for the mentioned packing unit only.

7. OPENING OF TECHNICAL AND FINANCIAL EVALUATION

The Bid will be scrutinized by Bid evaluation committee and inspection of manufacturing unit for compliance of WHO-GMP may be carried out by technical committee. Price Bid (BOQ) of the Bidder found eligible on satisfying the criteria for technical evaluation and inspection, will only be opened.

8. **BID SECURITY**

The Bid Security shall be @ Rs. 20,000/- for each item of Drugs & Medicines quoted subject to minimum of Rs. 2.00 lacs and maximum of Rs. 5.00 Lacs. In case Bid Security submitted by the bidder is at the minimum or more but number of quoted items is more than the Bid Security submitted, the quoted items by the bidder will be counted in sequence up to the Bid Security deposited. However without minimum Bid Security the offer will not be considered at all., Bid Security will not be taken from undertakings, corporation of GoI & GoR. Further, Bid Security will be taken @ Rs. 5,000/- per item of Drugs & Medicines quoted subject to minimum of Rs. 50,000/- and maximum of Rs. 1.25 Lacs, from SSI Units of Rajasthan. They will furnish copy duly attested by gazetted officer of the registration of SSI units issued by the Director of Industries in respect of the stores for which they are registered. Duly attested copy of Acknowledgement of EM-II issued by DIC with an affidavit worth Rs.10 as per Annexure-II under preference to Industries of Rajasthan rules 1995 in respect of stores for which they are registered. (Annexure-II). In case Bid Security submitted by the bidder is at the minimum or more but number of quoted items is more than the Bid Security submitted, the quoted items by the bidder will be counted in sequence up to the number matching the Bid Security deposited. However without minimum Bid Security the offer will not be considered at all.

The Bid Security shall be paid in through separate prescribed challans (format enclosed in Annexure-I) in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country upto 03.02.2016 or through D.D. / bankers cheque in favour of M.D. RMSCL physically in the office of RMSC by 1.30 PM on 04.02.2016 Bid security Deposit in any other form will not be accepted. Alternatively bidder may also deposit Bid document fees, Bid security and RISL processing fees by way of e-deposit, through Internet Banking by accessing RMSC website rmsc.nic.in clicking e-deposit icon following the laid down steps; Rs.25 plus applicable service tax will be the per transaction charge to be debited in respective depositor's account after successful e-deposit. Supplier should enclose the generated receipt.

The Bids submitted without sufficient Bid Security will be summarily rejected. The Bid Security will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails within specified time to sign the contract agreement or fails to furnish the performance security.

9. **OTHER CONDITIONS**

- The orders will be placed by the Managing Director or any officer designated, Rajasthan Medical Services Corporation Ltd, (hereinafter referred to as Ordering Authority).
- 2. The details of the required drugs, medicines, etc., are shown in Annexure-VIII. The quantity mentioned is only the tentative requirement and may increase or decrease as per the decision of Ordering Authority. The rates quoted should not vary with the quantum of the order or the destination. The commitment quantity for an item submitted by the bidder (in Annexure VII) shall be taken in to account and a bidder not having adequate capacity (as reflected in commitment quantity) may be technically disqualified.
- 3. Bid has been called for in the **generic names of drugs**. The Bidders should quote the rates for the generic products. The composition and strength of each product should be as per details given in **Annexure-VIII.** Any variation, if found, will

- result in rejection of the Bid. The products should conform to the specified standards IP/BP/USP. In case the product is not included in the said compendium, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing.
- 4. Rates (inclusive of Excise Duty, Customs duty, transportation, insurance, and any incidental charges, but exclusive of Sales tax) should be quoted for each of the required drugs, medicines etc., separately on door delivery basis according to the unit ordered. Bid for the supply of drugs, medicines, etc. with conditions like "AT CURRENT MARKET RATES" shall not be accepted. Handling, clearing, transport charges etc., will not be paid. The delivery should be made as stipulated in the purchase order placed with successful Bidders. No quantity or cash discount should be offered.

5.

- a) To ensure sustained supply without any interruption, the Bid Inviting Authority reserves the right to fix more than one supplier to supply the requirement among the qualified Bidders
- b) Orders will be placed periodically during rate contract period based on the stock positions only. Orders will be placed with L1 firms.
 - The orders may split between L-1 and rate matched firms. Quantities may be divided between L1 and matched L1 as 80:20. In case L2 and L3 match L1 than quantities may be divided as 75:15:10. Whenever L2 or L3 firms are more than one, then quantity would be distributed equally.
- c) After the conclusion of Price Bid opening, the lowest offer of the Bidder, if required will be considered for negotiations, and rate arrived after negotiations will be L-1 rate and L-1 supplier for an item of drugs/medicines for which the Bid has been invited.
- d) The Bidder who has been declared as L-1 supplier for certain item or items of drugs/medicines shall execute necessary agreement for the supply of the Bided quantity of such drugs/medicines as specified in the Bid document on depositing the required amount as performance security and on execution of the agreement, such Bidder is eligible for the placement of purchaser orders.

Moreover, purchase order can be placed after the issue of letter of

- acceptance, pending the execution of agreement and issuance of rate contract for an item.
- e) RMSC will inform the L1 rate to the Bidders who qualified for Price Bid opening, through RMSC web site or e-mail; willing bidders may inform in writing their consent to match with the L-1 rate for the item of the Drugs/Medicines quoted by them and the Bidders who agree to match L1 rate, will be considered as Matched L1.
- f) The Bidder, who agrees to match L-1 rate shall furnish the breakup detail (Rate, CST, VAT etc.) of price (L-1 rate).
- g) The supplier upon receipt of the purchase order deems that the purchase orders exceeds the production capacity declared in the Bid documents and the delay would occur in executing the order, shall inform the RMSC immediately without loss of time and the purchase orders shall be returned within 7 days from the date of the order, failing which the supplier is stopped from disputing the imposition of liquidated damages, fine for the delayed supply.
- h) If the L1 supplier has failed to supply /intimated RMSC about his inability/delay in supply as per the purchase order, the required Drugs/ Medicines within the stipulated time or as the case may be, RMSC may also place purchase orders with the Matched L1 Bidder for purchase of the Drugs/Medicines, provided such matched L1 Bidders shall execute necessary agreement indicating the production capacity as specified in the Bid document on depositing the required amount. Such Bidder is eligible for the placement of purchase orders for the item or items of Drugs/Medicines quoted by them.
- i) Subject to Para (h) above, while RMSC has chosen to place purchase orders with Matched L1 supplier and there are more than one such matched L1 suppliers, then the purchase orders for the requirement of Drugs/Medicines will be placed with L-2 first on matched rates of L-1 and in case L-2 does not have the required capacity than L-3 would be considered on matched L-1 rates and the same order would be followed in case of L-3, L-4 etc.

- j) The matched L1 supplier, on placement of purchase orders, will be deemed as L-1 rate supplier for the purpose of the Bid and all provisions of the Bid document applicable to L-1 rate Bidder will apply mutatis mutandis to the matched L1 supplier.
- k) If the purchase order quantity is very less (which do not make even a normal small batch size; order quantity is less than 1 lac Tab/Cap, or less than 10,000 injections/ bottles/ tubes), the supply may be allowed in brand name to ensure uninterrupted sustained supply. However, the label should possess the required logogram, and the price should not appear on the label.
- 6. The rates quoted and accepted will be binding on the Bidder during validity period of the bid and any increase in the price (except increase due to Excise Duty or any other statutory taxes) will not be entertained.
- 7. No Bidder shall be allowed at any time on any ground, whatsoever it may be, to claim revision or modification in the rates quoted by him after last date fixed for receipt of bid. Representation to make correction in the Bid documents on the ground of Clerical error, typographical error, etc., committed by the Bidders in the Bids shall not be entertained after submission of the Bids. Conditions such as "SUBJECT TO AVAILABILITY" "SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED" etc., will not be entertained under any circumstances and the Bids of those who have given such conditions shall be treated as incomplete and accordingly the Bid will be rejected.
- 8. The rates should be quoted only for the composition stated in the Bid.
- 9. Supplies should be made directly by the bidder and not through any other agency.
- 10. The Bidder shall allow inspection of the factory at any time by a team of Experts/Officials of the Bid Inviting Authority and or of the Govt. of Rajasthan. The Bidder shall extend all facilities to the team to enable to inspect the manufacturing process, quality control measures adopted etc., in the manufacture of the items quoted. If a Company/Firm does not allow for any such inspection, its Bids will be rejected. The firms/companies selected to supply the quoted product /products shall be inspected within 3 months after entering into contract with the firm.

10. ACCEPTANCE OF BID

- 1. The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria.
- 2. Bid Inviting Authority reserves the right to accept or reject the Bid for the supply of all or any one or more items of the drugs Bided for in a Bid without assigning any reason.
- 3. Bid Inviting Authority, or his authorized representative (s) has the right to inspect the factories of Bidders, before, accepting the rate quoted by them, or before releasing any purchase order(s), or at any point of time during the continuance of Bid and also has the right to reject the Bid or terminate/cancel the purchase orders issued and or not to reorder, based on adverse reports brought out during such inspections.
- 4. The acceptance of the Bids will be communicated to the successful Bidders in writing by the Bid inviting authority. Immediately after receipt of acceptance letter, the successful Bidder will be required to deposit PERFORMANCE SECURITY and agreement but not later than 15 days.
- 5. The approved rates of the successful Bidders would be valid as Rate contract and ending on **31.03.2018** (*w.e.f date of letter of acceptance*) and may extendable by 3 months.
- 6. Moreover, purchase order can be placed after the issue of letter of acceptance, pending the execution of agreement and issuance of rate contract for an item.

11. PERFORMANCE SECURITY

The Successful Bidders shall be required to pay performance Security Deposit @ 5% of the Contract value. Performance security will not be taken from undertaking, corporation of GoI & GoR.. The SSI Units of Rajasthan shall be required to pay Performance security @ 1% of the contract value.

The performance security shall have an upper limit of Rs 25 Lac to be deposited by a bidder at the time of signing of agreement (For one or many items). However, when the actual purchase orders cross a threshold for requiring additional security (remaining rate contract period with additional one year), the same will be required to be deposited by the supplier.

The performance guarantee should be paid upfront in respect of each contract on or before the due date fixed by Bid inviting authority in the form of Bank Guarantee (**Performa given in Annexure XIV**) in case the amount exceeds Rs 5 Lakhs. For amount of upto 5 Lakhs it should be deposited in the form of demand draft/bankers cheque issued by a scheduled bank or may be deposited through challan annexure 1 (the validity of bank guarantee should be for a period of thirty six month from the date of issuance of Bank Guarantee) in favor of the Managing Director, Rajasthan Medical Services Corporation Ltd, Payable at Jaipur, viz. Bid inviting authority before releasing the purchase order by the ordering authority. In case L-2 and L-3 bidders who have agreed to match L-1 price, then the *performance security* Deposit of L-2 and L-3 bidders will be 5% of value of their assured quantity (upper limit Rs 25 Lac) and in case L-4, L-5 and so on bidders who have agreed to match L-1 price bidders will be converted (Rs 20000/- per item) into security deposit. In case of inability of L-1 bidder to supply the required quantity of drugs, in that case the L-2 and L-3 supplier (as the case may be) will be asked to supply the drugs. At the time of placing of order these matched suppliers will be asked to deposit amount of balance security for a period of remaining rate contract period with additional one year.

Performance Security shall remain valid and refunded 60 days beyond the date of completion of all contractual obligations or after 36 months from the date of issuance of letter of acceptance, whichever is later.

12. AGREEMENT

a) The successful Bidder shall execute an agreement on a non-judicial stamp paper of value mentioned in the Acceptance Letter (stamp duty to be paid by the Bidder) within 15 days from the date of the intimation letter of intent by the Bid Inviting Authority, viz., the Managing Director, Rajasthan Medical Services Corporation Ltd. The Specimen form of agreement is available in Annexure-IV, failing to submission of performance security and execution of agreement within 15 days as stipulated, will result in forfeiture of Bid Security Deposit & other consequential action.

- b) The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any person or persons whatsoever.
- c) All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or left at the premises, places of business or abode.

13. SUPPLY CONDITIONS

- 1. Purchase orders along with the delivery destinations will be placed on the successful Bidder at the discretion of the Ordering Authority. Drugs and Medicines will be supplied at 34 District drug ware houses and 6 Medical College Warehouses of Rajasthan.
- 2. The supplier shall supply the entire ordered quantity before the end of **45 days** from the date of issue of purchase order at the destinations mentioned in the purchase order, if the above day happened to be a holiday for RMSC, the supply should be completed by 5.00 p.m. on the next working day. For drug items requiring sterility test and imported ones, the supply period will be **60 days** from the date of issue of purchase order.
- 3. All supplies will be scheduled for the period from the date of purchase order till the completion of the bid in installments, as may be stipulated in the purchase order.
- 4. Shelf Life: The labeled shelf life of drugs supplied should be not less than the period mentioned against each item in list of Drugs (Annexure-VIII). The remaining shelf life of the drugs at the time of delivery should not be less than ¾ of the labeled shelf life. Only those bidders shall quote who can manufacture and supply the product with the required shelf life. The product of labeled shelf life lesser than required shelf life will not be accepted. The product should not have such storage condition requiring it to be stored below 2°C. Quality Assurance: The supplier shall guarantee that the products as packed for shipment (a) comply with all provisions of specifications and related documents (b) meet the recognized standards for safety, efficacy and quality; (c) are fit for the purpose made; (d) are free from defects in workmanship and in materials and (e) the product has been manufactured as per WHO-GMP.

In case of imported items the remaining shelf life of 60% or more may be accepted with an undertaking that the firm will replace the unused expired stores with fresh goods. However, firms supplying drugs with remaining shelf life of 75% or more need not submit such undertaking.

- 5. The protocol of the tests should include the requirements given in I.P for tablets and those required specifically for the product specifications. The Bidder must submit its Test/ Analysis Report for every batch of drug along with invoice. In case of failure on the part of the supplier to furnish such report, the batch of drugs will be returned back to the supplier and he is bound to replenish the same with approved laboratory test report. The supplier shall provide the validation data of the analytical procedure used for assaying the components and shall provide the protocols of the tests applied and the placebo material when demanded for the purpose of testing.
- 6. The Drugs and medicines supplied by the successful Bidder shall be of the best quality and shall comply with the specification, stipulations and conditions specified in the Bid documents.
- 7. If supplies are not fully completed in **45 days** from the date of the Purchase Order (**60 days** for drugs of the category of serum, vaccine, enzymes, blood grouping reagents, biological products, powder for injections and imported drugs), the provisions of liquidated damages of Bid conditions will come into force. The Supplier should supply the drugs at the Warehouse specified in the Purchase Order and if the drugs supplied at a designated places other than those specified in the Purchase Order, transports charges will be recovered from the supplier.
- 8. If the supplier fails to execute at least 50% of the quantity mentioned in single purchase order and such part supply continues for three consecutive Purchase orders, then the supplier will be ineligible to participate in any of the Bids for particular items of drugs/medicines for a period of two year immediately succeeding year in which supplier has been placed Purchase order.
- 9. If the Bidder fails to execute the supply within the stipulated time, the ordering authority is at liberty to make alternative purchase of the items of drugs and

medicines for which the Purchase orders have been placed from any other sources (such as Public Sector undertakings at their rates, empanelled bidders, and bidders who have been technically qualified in the said bid) or in the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the Ordering Authority/Bid inviting authority has every right to recover the cost and impose penalty as mentioned in Clause 19, apart from terminating the contract for the default.

- 10. The order stands cancelled after the expiration of delivery period, and if the extension is not granted with or without liquidated damages. Apart from risk/alternate purchase action, the Bidder shall also suffer forfeiture of the performance security and shall invite other penal action like blacklisting/Debarring disqualification from participating in present and future Bids of Bid Inviting Authority/ordering authority. . (As per guidelines for blacklisting/ debarring at annexure- IX including amendment)
- 11. It shall be the responsibility of the supplier for any shortage/damage at the time of receipt at the designated places.
- 12. If at any time the Bidder has, in the opinion of the ordering authority, delayed in making any supply by reasons of any riots, mutinies, wars, fire. storm, tempest or other exceptional cause on a specific request made by the Bidder within 7 days from the date of such incident, the time for making supply may be extended by the ordering authority at its discretion for such period as may be considered reasonable. The exceptional causes do not include the scarcity of raw material, Power cut, labour disputes.
- 13. The supplier shall not be in any way interested in or concerned directly or indirectly with, any of the officers, subordinates or servants of the Bid Inviting Authority in any trade or business or transactions nor shall the supplier give or pay promise to give or pay any such officers, subordinates or servants directly or indirectly any money or fee or other considerations under designation of "Customs" or otherwise, nor shall the supplier permit any person or persons whom so ever to interfere in the management or performance hereof under the

- power of attorney or otherwise without the prior consent in writing of the Bidder Inviting Authority.
- 14. If the supplier, or any of its approved items gets debarred/banned/blacklisted in any states after entering into agreement with RMSC, it shall be the responsibility of the supplier to inform RMSC without any delay about the same.
- 15. If a supplier fails to execute two successive orders, in full, firm will be liable for debarment the particular product, for a year.
- 16. If a supplier fails to execute first order, without proper justification, a show cause notice may be given to him to respond within 7 days. If it does not respond or does not give reasonable justification, the corporation may order to L-2 and L-3, for entire failed supply on L-1 matched rate. If L-2 and L-3 matched rates are not available, then only purchase may be made on 'Risk and cost basis' as being done presently. Subject to other condition of Bid documents.

14. LOGOGRAMS / Markings

Logogram means, wherever the context occurs, the design as specified below:-

DESIGNS FOR LOGORAMS

INJECTIONS

Injection in ampoule form should be supplied either in Double constricted neck ampoules or snap off type ampoules with the label bearing the words "Rajasthan Govt. Supply- Not for sale निःशुल्क वितरण हेत्, QC – Passed" overprinted and the following logogram which will distinguish from the normal trade packing. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.



The vials should be supplied with aluminum seals containing the following logogram:



LIQUIDS

Liquid preparations should be in bottles with pilfer-proof caps bearing the following logogram:



The top of the cap and the label to be affixed on the containers should bear a distint colour different from the colour of the label of the trade packs and they should be overprinted in red colour with the words "Rajasthan Govt. Supply- Not for Sale नि:शुल्क वितरण हेतु, QC – Passed" and the logogram. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.



OINTMENTS & CREAMS

Ointments & Creams should be supplied in tubes bearing the following logograms and the words "Rajasthan Govt. supply- Not for sale নি: খুল্ক বিন্ন্ QC – Passed" overprinted. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.



TABLETS & CAPSULES

Tablets and Capsules should be supplied in Strips or Blisters or as mentioned in the list of items for bid. The strip, etc, should bear the following logograms and the words "Rajasthan Govt. supply- Not for sale निःशुल्क वितरण हेतु, QC – Passed" overprinted. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.



SPECIMEN LABEL FOR OUTER CARTON

SHALL BE OF DIFFERENT COLOURS FOR DIFFERENT CLASS OF DRUGS

RAJASTHAN GOVT. SUPPLY NOT FOR SALE

(Name of Drugs etc.)

CONSTITUENTS OF.....

Name of the Drug, Manufactured by, Batch no Mfg.Date, Exp. Date, Quantity/Kit

Net. Weight:....Kg

Manufactured by/Assembled by

The name of the drug shall be mentioned in Hindi and English and should be legible and be printed more prominently. A uniform colour theme and artwork will be necessary. Apart from this "For Govt. of Rajasthan – Not for Sale निःशुल्क वितरण हेतु, QC – Passed" along with logo of RMSCL will be printed on each strip/label of the bottle. The storage directions should be clear, legible and preferably with yellow highlighted background.

- 1. Bids for the supply for Drugs and medicines etc., shall be considered only if the Bidder gives undertaking in his Bid that the supply will be prepared and packed with the logogram printed on the strips of tablets and capsules and labels of bottles, ampoules and vials etc., as per the design mentioned above.
- 2. All tablets and capsules have to be supplied in standard packing in aluminum strip or blisters with aluminium foil back with printed logogram and shall also conform to schedule P1 of the Drugs & Cosmetics Act & Rules wherever it applies. Affixing of stickers and rubber stamps shall not be accepted.
- 3. Labels of Vials, Ampoules and Bottles containing the items Bided for should also carry the logogram.
- 4. Failure to supply Drugs etc., with the logogram will be treated as breach of the terms of agreement and liquidated damages will be deducted from bills payable as per conditions in Clause 18.2 Bidders who are not willing to agree to conditions above will be summarily rejected.
- 5. In case of imported drugs affixing rubber stamp on the original label is allowed with indelible ink on inner most and outer packing.

15. PACKING

- 1. The item shall be supplied in the package schedule given below and the package shall carry the logogram specified in clause -14. The labeling of different packages should be as specified below. The packing in each carton shall be strictly as per the specification mentioned. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties.
- 2. The pediatric drops should always be supplied with dropper. A measuring cap with suitable markings must be provided for other paediatric oral liquid preparations.
- 3. The labels in the case of injectables should clearly indicate whether the preparations are meant for IV, IM, SC, etc.
- 4. Injection vials should have flip off seals.
- 5. All plastic containers should be made of virgin grade plastic.
- 6. The name of the drug should be printed in clearly legible bold letters (It is advisable that the colour of font be different from other printed matter to make the name highly conspicuous.
- 7. It should be ensured that only first hand fresh packaging material of uniform size is used for packing. All packaging must be properly sealed and temper proof.
- 8. All packing containers should strictly conform to the specifications prescribed in the relevant pharmacopoeia/Act.
- 9. Packing should be able to prevent damages or deterioration during transit.
- 10. In the event of items supplied found to be not as per specifications in respect of their packing, the Ordering Authority is at liberty to make alternative purchase of the item for which the purchase orders have been placed from any other sources or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier. In such cases the ordering authority has every right to recover the cost and impose penalty as mentioned in Clause 18.2 and 19.

I. SCHEDULE FOR PACKAGING OF DRUGS AND MEDICINES GENERAL SPECIFICATIONS

No corrugate package should weigh over 15 kgs (i.e. product + inner carton + corrugated box).

All items should be packed only in first hand strong boxes only.

Every corrugated box should preferably be of single joint and not more than two joints.

Every box should be stitched using pairs of metal pins with an interval of two inches between each pair.

The flaps should uniform meet but should not overlap each other. The flap when turned by 45-60 should not crack.

Every box should be sealed with gum tape running along the top and lower opening.

CARRY STRAP:

Every box should be strapped with two parallel nylon carry straps (they should intersect.)

LABEL:

Every corrugated box should carry a large outer label clearly indicating that the product is for "Rajasthan Govt. Supply-Not for Sale".

The Product label on the cartoon should be large, at least 15 cms x 10 cms dimension. It should carry the correct technical name, strength or the product, date of manufacturing, date of expiry quantity packed and net weight of the box.

OTHERS:

NO box should contain mixed products or mixed batches of the same product.

II. SPECIFICATION FOR CORRUGATED BOXES HOLDING TABLETS/CAPSULES/PESSARIES

1. The total weight of the box should be approx of 7-8 Kgs.

III. SPECIFIATION FOR LARGE VOLUME BOTTLE i.e., ABOVE 100 ml AND BELOW 1 LIT.

1. All these bottles should be packed only in single row with partition between each and also with top and bottom pad of 3 ply.

IV. SPECIFICATION FOR IV FLUIDS

Each corrugated box may carry maximum of only 24 bottles of 500 ml in a single row or 50 bottles of 100 ml in 2 rows with individual sealed polythene cover and centre partition pad, top and bottom pads of 3 ply.

V. SPECIFICATION FOR LIQUID ORALS

100 bottles of 50 ml or 60 ml may be packed in a single corrugated in 2 rows with top, bottom and centre pad of 3 ply.

50 bottles of 100 ml - 120 ml may be packed in a similar manner in a single corrugated box.

If the bottles are not packed in individual carton, 3 ply partition should be provided between each bottle. The measuring device should be packed individually.

VI. SPECIFICATION FOR OINTMENT/CREAM/GELS PACKED IN TUBES:

No corrugated box should weigh more than 7-8 Kgs.

Every Ointment/Cream/Gel tube should be individually packed in carton and then packed in 20's in a grey board box, which may be packed in a corrugated box.

VII. SPECIFICATIONS FOR INJECTION (IN VIALS AND AMPOULES)

Vials may be packed in corrugated boxes weighing upto 15 Kgs. Ampoules should be packed in C.B weighing not more than 8 Kgs.

In the case of 10 ml Ampoules or 50 ampoules may be packed in a grey board box. Multiples of grey board boxes packed in CB. In case of ampoules larger than 10 ml only 25 ampoules may be packed in a grey board box with partition.

If the vial is packed in individual cartoon, there is no necessity for grey board box packing. The individual cartoon may be packed as such in the CB with centre pad.

In case of ampoules every grey board box should carry 5 amps alongwith Cutters placed in a polythene bag.

Vials of eye and ear drops should be packed in a individual cartoon with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a grey board box.

Cutters are not required with ampoules in the case of snap off type ampoules.

VIII. SPECIFICATION FOR ORS

Primary Packing:- The pouches/sachets of ORS should be three layered with following composition

| Site | Material | Micron | MM | g/m ² |
|---------|--------------|--------|-------------|------------------|
| Inner | Polyethylene | 50 | 0.040-0.050 | 36.9-46.1 |
| Middle | Aluminium | 09 | 0.009-0.015 | 24.3-40.5 |
| Outside | Polyester | 12 | 0.012-0.015 | 12.9-20.9 |

Secondary Packages and Tertiary package:-

50 sachets may be packed in grey board boxes and 10 grey board boxes in a C.B.

IX. LYSOL

Not more than four 5 liters cans may be packed in a single Box.

16. **QUALITY TESTING**

- 1. Sampling of supplies from each batch will be done at the point of supply or distribution/storage points for testing. (The samples would be sent to different empanelled laboratories for testing by the ordering authority after coding). The RMSC will deduct a sum of 1.5% from the amount of bill payable to supplier on account of handling and testing charges.
- 2. The Drugs shall have the active ingredients within the permissible level throughout the shelf life period of the drug. The samples may also be drawn periodically during the shelf life period. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirements shall render the relevant batches liable to be rejected. If the sample is declared to be Not of Standard Quality or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.
- 3. In the event of the samples of the Drugs and medicines supplied failing quality tests or found to be not as per specification the ordering authority is at liberty to make alternative purchase of items of drugs and medicines for which the Purchase orders have been placed from any other sources or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the ordering authority has every right to recover the cost and impose penalty as mentioned in Clause 19.

- 4. The supplier shall furnish to the purchaser the evidence of bio-availability and/or bio-equivalence for certain critical drugs when asked for. If there is any problem in the field the B.M.R/B.P.R for the particular batch shall also be supplied when demanded.
- 5. The products should conform to the standards of IP/BP / USP as the case may be. In case the product is not included in the said compendium, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing. For imported drugs respective countries pharmacopeia standards shall be acceptable (even if the product is official in IP)
- 6. The supply of any item shall be considered complete for the purpose of calculation of liquidated damages only when reference standards/ standard testing procedure or test protocol/placebo materials are made available to the corporation along with the supply of items as per the purchase order. However these materials and documents shall be made available by supplier to Quality Cell of RMSC Headquarter. Such requirement will however be indicated in the purchase order.

17. PAYMENT PROVISIONS

- 1. No advance payment towards costs of drugs, medicines etc., will be made to the Bidder.
- 2. On receipt of the prescribed consolidated invoice duly stamped and signed by authorized signatory and analytical laboratory report regarding quality, the payment would be made in 30 days. (Annexure- XIII & XIV)
- 3. The in charge of district drug warehouse (DDW) will acknowledge the drugs received & ensure entry in e- Aushadhi software online.
- 4. All bills/ Invoices should be raised in duplicate and in the case of excisable Drugs and Medicines; the bills should be drawn as per Central Excise Rules in the name of the authority as may be designated. The supplier will deliver following document at the time of delivery at DDW.
 - a. In house test report of drug.
 - b. The challan / invoice copy pertaining to DDW
- 5. Payments for supplies will be considered after receipt of reports of standard quality on samples having been tested approved laboratories of ordering

authority. Furthermore, in case the supplies do not meet the ordered quantities, following condition shall apply.

- (i) If a bidder fails to supply the complete quantity (but has supplied at least 70%) of an item ordered in the Purchase Order, a penalty @ 10% of the value of unsupplied/short supplied quantity, shall be levied. The minimum penalty shall be Rs 1000/- in case if it comes to less than this amount by calculation.
- (ii) If a bidder fails to supply even 70% of the quantity of an item ordered in the Purchase Order, an extra penalty @ 2% in Purchase Order value shall be levied in addition to the penalty referred to in Para 17(5) (i) above.
- 6. If at any time during the period of contract, the price of Bided items is reduced or brought down by any law or Act of the Central or State Government or by the Bidder himself, the Bidder shall be bound to inform ordering authority immediately about it. Ordering authority empowered to unilaterally effect such reduction as is necessary in rates in case the Bidder fails to notify or fails to agree for such reduction of rates.

In case the price of a drug fixed by NPPA (Govt of India) under applicable DPCO is less than the RMSC contract price, the supplier shall be bound to make the supplies of such items at price fixed by the Govt.

7(a) In case of any enhancement in Excise Duty due to notification of the Government after the date of submission of Bids and during the Bid period, the quantum of additional excise duty so levied will be allowed to be charged extra as a separate item without any change in the basic of the price structure price of the Drugs approved under the Bid. For claiming the additional cost on account of the increase in Excise Duty, the Bidder should produce a letter from the concerned Excise authorities for having paid additional Excise Duty on the goods supplied to ordering authority and also must claim the same in the invoice separately.

Similarly if there is any reduction in the rate of essential drug, as notified by the Govt., after the date of submission of Bid, the quantum of the price to the extent of reduction of essential drug will be deducted without any change in the basic price of the price structure of the drugs approved under the Bid.

7(b) In case of successful bidder has been enjoying excise duty exemption on any criteria of Turnover etc., such bidder will not be allowed to claim excise duty at

- later point of time, during the tenure of contract, when the excise duty is chargeable on goods manufactured.
- 8. (i) If the supplier requires an extension in time for completion of contractual supply, on account of occurrence of any hindrance he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of completion of supply.
 - (ii) The purchase Officer may extend the delivery period with or without liquidated damages in case they are satisfied that the delay in the supply of goods is on account of hindrances. Reasons shall be recorded.
 - (iii) **Extension in delivery period:-** In case of extension in the delivery period with liquidated damages the recovery shall be made on the basis of following percentages of value of stores which the Bidder has failed to supply:-
- a) Delay upto one fourth period of the prescribed delivery period; 2.5%
- b) Delay exceeding one fourth but not exceeding half of the prescribed delivery period; 5%
- c) Delay exceeding half but not exceeding three fourth of the prescribed delivery period; 7.5%
- d) Delay exceeding three fourth of the prescribed delivery period; 10%
 - Note 1:- Fraction of a day in reckoning period of delay in supplies shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.
 - Note 2: In specific condition, permission for additional delay of 10 days may be granted for supply, in such a case an additional penalty of 5% shall be levied.
 - Note 3:- If a supplier seeks extension in supply period beyond two times the time indicated in purchase order, the supply period shall be extended with the condition that if the rate received in new bid(s) invited are lower than the rate contract in operation, then the supplier shall be entitled to the lower rates so received.
- 9. If, at any time during the continuance of this Agreement, the Supplier has, in the opinion of the Purchaser, delayed in making any supply ordered, by the reasons of any riots, mutinies, ears, fire, storm, tempest or other exceptional cause, on a

specific request made by the Supplier, the time for effecting delivery may be extended by the Purchaser surely at his discretion for such period as may be considered reasonable by the Purchaser. No further representation from the Supplier will be entertained on this account.

18. <u>DEDUCTION IN PAYMENTS:</u>

- 1. If the supply is received in damaged conditions it shall not be accepted.
- 2. All the Bidder are required to supply the product with logogram and with prescribed packing specification. If there is any deviation in these Bid conditions a separate damages will be levied @ 2% irrespective of the ordering authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause **No.15.10**.

19. QUALTIY CONTROL DEDUCTION & OTHER PENALTIES:

- 1. If the successful Bidder fails to execute the agreement and/or to deposit the required performance security within the time specified or withdraws his Bid after the intimation of the acceptance of his Bid has been sent to him or owing to any other reasons, he is unable to undertake the contract, his contract will be cancelled and the Bid security Deposit deposited by him along with his Bid, shall stand forfeited by the Bid Inviting Authority and he will also be liable for all damages sustained by the Bid Inviting Authority apart from blacklisting/ debarring at annexure IX including amendment)
- 2. If the samples drawn from supplies do not conform to statutory standards, the supplier will be liable for relevant action under the existing laws and the entire stock in such batch should be taken back by the supplier within a period of 30 days from the issue of letter from ordering authority the information of which may be communicated by e- mail. The stock shall be taken back at the expense of the supplier. Ordering authority has the right to destroy such NOT OF STANDARD DRUGS IF THE SUPPLIER does not take back the goods within the stipulated time. Ordering authority will arrange to destroy the NOT OF STANDARD drugs within 90 days after the expiry of 30 days mentioned above, without further notice, and shall also collect demurrage charge calculated @ 2% per week on the value of the drugs rejected till such destruction.

The Supplier shall replace the stock of NOSQ goods with fresh goods upon intimation to do so by the ordering authority.

- 3. The supplier will not be entitled to any payment whatsoever for Items of drugs found to be of NOT OF STANDARD QUALITY whether consumed or not consumed and the ordering authority is entitled to deduct the cost of such batch of drugs from the any amount payable to the Bidder. On the basis of nature of failure, the product/supplier will be moved for Black Listing. (As per guidelines for blacklisting/ debarring at annexure IX including amendment)
- 4. For supply of drugs of NOT OF STANDARD QUALITY the respective Drugs Controller will be informed for initiating necessary action on the supplier and that the report of product shall be sent to the committee for appropriate action including blacklisting. (As per guidelines for blacklisting/ debarring at annexure IX including amendment)
- 5. The decision of the ordering authority or any Officer authorized by him as to the quality of the supplied drugs, medicines etc., shall be final and binding.
- 6. Ordering Authority will be at liberty to terminate without assigning any reasons thereof the contract either wholly or in part on 30 days notice. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.
- 7. For infringement of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the ordering authority, and the supplier shall be liable for all losses sustained by the ordering authority, in consequence of the termination which may be recovered personally from the supplier or from his properties, as per rules.
- 8. Non performance of any contract provisions shall be examine and may disqualify the firm to participate in the future Bids.
- 9. In the event of making ALTERNATIVE PURCHASE, as specified in Clause 13.10, Clause 15.10 and in Clause 16.3 the penalty will be imposed on supplier apart from forfeiture of Security Deposit. The excess expenditure over and above contracted process incurred by the ordering authority in making such purchases from any other sources or from the open market or from any other Bidder who has quoted higher rates and other losses sustained in the process, shall be recovered from the performance security or from any other money due and

become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier.

- 10. In all the above conditions, the decision of the Bid Inviting Authority, viz Managing Director, Rajasthan Medical Services Corporation Ltd, would be final and binding; in case of any dispute regarding all cases under Bid procedure or in any other non-ordinary situation and would be acceptable to all.
- 11. All litigations related to the supplier for any defaults will be done by Bid Inviting Authority and his decision will be final and binding.

20. EMPANELMENT OF FIRMS

RMSC invites Applications from eligible firms for Empanelment for supply of Drugs & Medicines mentioned in Annexure- VIII for one year. The empanelment would entitle a firm to participate in RMSC for limited bids. Such situations may normally arise when the open bid for a Drugs & Medicines fails and there is an urgency to purchase it, or when the L-1 bidder has fail to supply, or the rate contract of an item ceases to exist for any reason. The Bidder has to submit an undertaking in the format given at Annexure-XI.

The empanelment can be renewed for the next one year term on payment of the empanelment fee as applicable at the time of renewal.

21. SAVING CLAUSE

No suit, prosecution or any legal proceedings shall lie against Bid Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of Bid.

22. <u>JURISDICTION</u>

In the event of any dispute arising out of the Bid or orders such dispute would be subject to the jurisdiction of the Courts of Jaipur or Honorable High Court (Jaipur Bench **only**).

23. CORRECTION OF ARITHMETIC ERRORS:

Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

(i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit

price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;

- (ii) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.
- (iii) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.

If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.

24. PROCURING ENTITY'S RIGHT TO VARY QUANTITY:

(i) At the time of award of contract, the quantity of Drugs, originally specified in the bidding documents may be increased or decreased. There will not be any minimum quantity guaranteed against bid quantity. The bid quantity is only indicative. Actual purchase can be more or less than the bid quantity based on actual consumption in the hospitals during Rate Contract period.

The supplier shall submit the supply commitment quantity' in Annexure **VII at point no. 3** which will be used for the cases where the actual purchase quantity tends to increase substantially from the bid quantity.

- (ii) If the procuring entity does not procure any subject matter of procurement or procures less than the quantity specified in the bidding documents due to change in circumstances, the bidder shall not be entitled for any claim or compensation except otherwise provided in the conditions of contract.
- (iii) However a bidder is bound to supply up to quantity indicated in bid document, considering the total production capacity & capacity dedicated

to RMSC. Moreover, the actual purchases beyond Bid quantity may be made keeping in view the supply commitment of bidder to corporation.

25. <u>DIVIDING QUANTITIES AMONG MORE THAN ONE BIDDER AT (IN CASE OF PROCUREMENT OF GOODS):</u>

The orders may split between L-1 and rate matched firms. Quantities may be divided between L1 and matched L1 as 80:20. In case L2 and L3 match L1 than quantities may be divided as 75:15:10. Whenever L2 or L3 firms are more one, then quantity would be distributed equally.

26. GRIEVANCE REDRESSAL DURING PROCUREMENT PROCESS:

The Designation and address of the First Appellate Authority is *Special Secretary* / Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan.

The Designation and address of the Second Appellate Authority is Principal Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan and Chairman, RMSCL.

i. Filling an appeal

If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:

Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings:

Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.

ii. The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.

iii. If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of receipt of the order passed by the First Appellate Authority, as the case may be.

iv. Appeal not to lie in certain cases

No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-

- (a) Determination of need of procurement;
- (b) Provision limiting participation of Bidders in the Bid process; (c) The decision of whether or not to enter into negotiations;
- (d) Cancellation of a procurement process;
- (e) Applicability of the provisions of confidentiality.

v. Form of Appeal

- (a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.
- (b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.
- (c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorised representative.

vi. Fee for filling appeal

- (a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.
- (b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.

vii. Procedure for disposal of appeal

- (a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.
- (b) On the date fixed for hearing, the First Appellate Authority or Second Appellate

Authority, as the case may be, shall,-

- (i) Hear all the parties to appeal present before him; and
- (ii) Peruse or inspect documents, relevant records or copies thereof relating to the matter.
- (c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.
- (d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.

27. <u>COMPLIANCE WITH THE CODE OF INTEGRITY AND NO</u> CONFLICT OF INTEREST:

Any person participating in a procurement process shall-

- a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;
- b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;
- c) Not indulge in any collusion, Bid rigging or any-competitive behaviour to impair the transparency, fairness and progress of the procurement process;
- d) Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;
- e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;

- f) Not obstruct any investigation or audit of a procurement process;
- g) Disclose conflict of interest, if any; and
- h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

Conflict of interest:-

The Bidder participating in a bidding process must not have a Conflict of Interest.

A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.

- I. A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:
- a. Have controlling partners/shareholders in common; or
- b. Receive or have received any direct or indirect subsidy from any of them; or
- c. Have the same legal representative for purposes of the Bid; or
- d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or
- e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or
- f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or
- g. Bidder or any of its affiliates has been hired (or is proposed to be hired0 by the Procuring Entity as engineer-in0chage/ consultant for the contract.

28. FALL CLAUSE

The prices under a rate contract shall be subject to price fall clause. If the rate contract holder quotes / reduces its price to render similar goods, works or services at a price lower than the rate contract price to anyone in the State at any time during the currency of the rate contract, the rate contract price shall be automatically reduced with effect from the date of reducing or quoting lower price, for all delivery of the subject matter of procurement under that rate contract and the rate contract shall be amended accordingly. The firms holding parallel rate contracts shall also be given opportunity to reduce their price by notifying them the reduced price giving them fifteen days time to intimate their acceptance to the revised price. Similarly, if a parallel rate contract holding firm reduces its price during currency of the rate contract, its reduced price shall be conveyed to other parallel rate contract holding firms and the original rate contract holding firm for corresponding reduction in their prices. If any rate contract holding firm does not agree to the reduced price, further transaction with it, shall not be conducted.

Managing Director Rajasthan Medical Services Corporation

| 5 |
|----------|
| 3 |
| * |
| S |
| (D) |
| ш |

Customer Copy

| | ANNEXURE-I | 1 |
|-----------------------------------|--|---------------------------------------|
| Acknowledgement | AUTION: USE "FCMBR" M Institute Name Institute ID DETAILS OF THE SUPPLIER Supplier Name Tender Ref. No. Type of Deposit fees/Others Mobile No. Cash Deposit: Ioon * 500 * 100 * 500 * 100 * | , , , , , , , , , , , , , , , , , , , |
| For Bank use only Cashier/Officer | Institute Name Institute Name Supplier Name Tender Ref. No. Cash Deposit: Constitute No. Commission Commission Constitute No. Commission Commission Constitute No. Commission | "ME" do ay engina e lo trace |
| Acknowledgement | Branch Institute Name Institute ID DETAILS OF THE SUPPLIER Supplier Name Tender Ref. No. Type of Deposit: Denomination Total Amount (in words): ₹ Name of the Depositor Signature Address for communication | |
| | Rajasthan Rajast | |
| For Bank use only | Customer Cop Jab national bank DIST. NO. AIR Medical Services Corporation, Jaipur RMSCJ - A/c No. 2246002100024414 Date of Deposit Date of Deposit DD MM YY One out of - Tender Fees/EMD/SD/ Tender Processing Cheque Deposit: Chal fee payable * One of Bank Total amount * One of Bank | |
| Cashier/Office | Customer Copy DIST. NO. DIST. NO. I alpur 100024414 MM YY MM YY Bank ₹ P | |

0 0

Ps

Cashier/Officer

Format of Affidavit (On Non Judicial Stamp Paper of Rs. 10/-)

| I | S | S/o | Age | Yrs | |
|------------------------------|--------------------|--|---------------|--|------------------|
| residing | at | Proj | orietor/Partr | ner/Director | of |
| M/s | do hereby | solemnly affirm | and declare | that: | |
| (a) My/Our a | above noted ent | terprises M/s | | | has been |
| issued ackno | owledgement of | f Entrepreneurial | Memoran | dum Part-I | I by the |
| Districts Inc | dustries Center | r | The acl | knowledgen | nent No. |
| | | and | | | |
| following iter | ms. | | | | |
| (i) (ii) (iii) (iv) | | | | | |
| (v) (b) My/Our a | above noted ac | knowledgement o | of Entreprer | neurial Men | norandum |
| - | | ed or withdrawn b | _ | | |
| that the enter | prise is regularly | y manufacturing tl | he above ite | ms. | |
| | | ving all the requi | | | ery and is |
| • | - | e the above noted | - | | • |
| Place | | | orized Sign | Proprietor/D atory with R and date | |
| | | VERIFICATIO | ON | | |
| I | | S/o | | Aged | Yrs |
| at | residing | Proprietor/Part verify and confect to the best of | ner/Director | r contents at | of (a), (b) & |

DEPONENT

ANNEXURE-III Ref. Clause No. 5 (m)

ANNUAL TURN OVER STATEMENT

| The Annual Turn | over (for drugs and medicines | er (for drugs and medicines including Surgical and | | | | |
|-------------------------|--------------------------------------|--|--|--|--|--|
| sutures | Business) | of | | | | |
| M/s | t | for the past three years | | | | |
| are given below and cer | tified that the statement is true as | nd correct. | | | | |

| S.No. | Years | Turnover i | n Lakhs (Rs) |
|-----------------------------|---------|------------|--------------|
| 1 | 2011-12 | | |
| 2 | 2012-13 | | |
| 3 | 2013-14 | | |
| | Total | Rs. | Lakhs |
| Average turnover per annual | | Rs. | Lakhs |

Or

| S.No. | Years | Turnove | r in Lakhs (Rs) |
|-----------------------------|---------|---------|-----------------|
| 1 | 2012-13 | | |
| 2 | 2013-14 | | |
| 3 | 2014-15 | | |
| | Total | Rs. | Lakhs |
| Average turnover per annual | | Rs. | Lakhs |

| Date: | Signature of Auditor/ |
|-------|-----------------------|
| | Chartered Accountant |
| Seal: | (Name in Capital) |

AGREEMENT

| This Deed of | Agreement | is made on this | | | | day |
|-----------------|---------------|-------------------|-------------|----------|----------------|------------|
| of | | | | | | |
| | | 2016 | by | M/s | • | |
| represented b | y its Propr | rietor/Managing | partner/N | /Ianagi | ng Director | having its |
| Registered | | | Office | | | at |
| | | | | | _and its Fac | tory |
| Premises | | | | | | at |
| (hereinafter r | referred to a | as "Supplier" wh | nich term | shall | include its s | uccessors, |
| representative | es, heirs, e | xecutors and a | dministra | itors u | nless exclud | ed by the |
| Contract) on | one part | and Rajasthan | Medical | Servi | ices Corpora | ntion Ltd, |
| represented b | y its Execu | tive Director (P) | having is | s office | e at Swasthya | a Bhawan, |
| Tilak Marg, | C-Scheme, | Jaipur (hereina | after refe | erred to | o as "The F | urchaser" |
| which term s | hall include | e its successors, | represent | atives, | executors as | ssigns and |
| administrator | unless excl | uded by the Con | tract) on | the oth | er part. | |
| Where | as the Sup | plier has agreed | to supply | y to the | e Purchaser, | the Drugs |
| and Medicine | es with spec | cifications menti | oned in t | he Sch | edule attach | ed here to |
| at the prices | noted the | re in and in th | e manne | er and | under the t | erms and |
| conditions he | ere in after | mentioned and | where a | s the S | Supplier has | deposited |
| with | the | Purchaser | | a | sum | of |
| Rs | | | | | | _(Rupees |
| only) as Per | formance S | ecurity for the | due and | faithfu | ıl performan | ce of this |
| Agreement, | to be forfe | eited in the eve | nt of the | e Supp | olier failing | duly and |
| faithfully to 1 | perform it. | Now these prese | nts witne | ess that | for carrying | duly and |
| faithfully to | perform it. | Now these pres | ents witn | ess tha | at for carryin | ng out the |
| said Agreeme | ent in this b | ehalf into execut | tion the S | Supplie | r and the Pu | rchaser do |
| hereby mutua | ally covena | nt, declare, cont | ract and | agree | each of them | n with the |
| other of them | in the man | ner following, th | at is to sa | ıy, | | |

- 1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation, (Two year Rate Contract ending on 31.03.2018) (NIB No. F.02(169)/RMSC/PROCURMENT/ DRUG/NIB-01/2015/01 Dated:01.01.2016) and technical bid opened on 04.02.2016), the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.
- 2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.
 - (b) This Agreement shall be deemed to have come into force with effect from *the date of issuance of letter of acceptance*and it shall remain in force upto 31.03.2018.
 - (c) The Bid quantity noted against each item in the schedule attached hereto indicates only the probable total requirements of the Purchaser in respect of each item for the Agreement Period indicated in Clause (b) above. This quantity may increase or decrease at the discretion of the Purchaser. The Supplier shall make supplies of the Drugs and Medicines on the basis of the Purchaser Orders placed on him from time to time by the ordering Authorities of the purchaser specifying the quantities required to be supplied required to be supplied at the specific location in the state of Rajasthan.

TERMINATION OF CONTRACT ON BREACH OF CONDITION

- 1 (a) In case the Supplier fails or neglects or refuse to faithfully perform any of the Covenants on his part herein contained, it shall be lawful for the Purchaser to forfeit the amount deposited by the Supplier as PERFORMANCE SECURITY and cancel the Contract.
 - (b) In case the Supplier fails, neglects, or refuse to observe, perform, fulfill and keep, all or any one or more or any part of any one of the Covenants, stipulation and provisions herein contained, it shall be lawful for the Purchaser on any such failure, neglect or refusal, to put an end to this Agreement and

thereupon every article, cause and thing herein contained on the part of the Purchaser shall cease and be void, and in case of any damage, loss, expenses, difference in cost or other moneys from out of any moneys for the time being payable to the Supplier under this and/or any other Contract and in case such last mentioned moneys are insufficient to cover all such damages, losses, expenses, difference in cost and other moneys as aforesaid, it shall be lawful for the Purchaser to appropriate the Performance Security made by the Supplier as herein before mentioned to reimburse all such damages, losses, expenses, difference in cost and other money as the Purchaser shall have sustained, incurred or been put to by reason of the Supplier having been guilty of any such failure, negligence or refusal as aforesaid or other breach in the performance of this Contract.

- (c) If at any time during the course of the Contract, it is found that any information furnished by the Supplier to the Purchaser, either in his Bid or otherwise, is false, the Purchaser may put an end to the Contract/Agreement wholly or in part and thereupon the provisions of Clause (a) above shall apply.
- 2 The Purchaser reserves the right to terminate without assigning any reasons therefore the Contract/Agreement either wholly or in part without any notice to the Supplier. The Supplier will not be entitled for any compensation whatsoever in respect of such termination of the Contract/Agreement by the Purchaser.

NOTICE ETC, IN WRITING

3 All Certificates or Notice or orders for time or for extra, varied or altered supplies which are to be the subject of extra or varied charges whether so described in the Agreement or not, shall be in writing, and unless in writing, shall not be valid, biding or be of any effect whatsoever.

SUPPLIERS NOT HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATES

4 The Supplier shall not be in any way interested in or concerned directly or indirectly with, any of the Officers, Subordinate or Servants of the Purchaser. In any trade, business or transactions nor shall the Supplier give or pay or promise to give or pay any such Officer, Subordinate or Servant directly or indirectly any money or fee or other consideration under designation of

"Custom" or otherwise; nor shall the Supplier permit any person or persons whomsoever to interfere in the management or performance hereof under power of attorney or otherwise without the consent in writing the consent in writing of the Purchaser obtained in first hand.

BANKRUPTCY OF THE SUPPLIER

5 In case the Supplier at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of bankruptcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the Purchaser to put an end to the Agreement, and thereupon every article, clause and thing herein contained to be operative on the part of the Purchaser, shall cease and be void and the Purchaser shall have all the rights and remedies given to him under the preceding clauses.

SERVING OF NOTICE ON SUPPLIER

- 6 All notice or communication relating to or arising out of this Agreement or any of the terms thereof shall be considered duly served on or given to the Supplier if delivered to him or left at his premises, place of business or abode.
- 7 And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any of clause herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of the Managing Director, Rajasthan Medical Services Corporation Ltd in the matter shall be final and binding.
- 8 All disputes arising out of this agreement and all questions relating to the interpretation of this agreement shall be decide by the Govt. and the decision of the Govt. shall be final.

SUPPLIER (Signature, Name EXECUTIVE DIRECTOR (P), & Address With Stamp)

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

Witness (Signature, Name & Address)

Witness

1.

2.

ANNEXURE – V Ref. Clause No. 5 (u)

Check List

| Section | | Document Type | Yes/No |
|---------|-------------------|--|----------|
| | requirement | | TO \$7 |
| | | | If Yes |
| | DID CECUDITY | Challer/DD/ a deposit concreted receipt of | Page No. |
| A | BID SECURITY | Challan/DD/ e-deposit generated receipt of | |
| | DEPOSIT, RISL | Bid Security Deposit, bid fee and RISL fee and | |
| | Fess, Bid | SSI certificate for exemption with Annexure-II | |
| | Processing Fees, | | |
| | Empanelment Fees. | | |
| В | Technical | Manufacturing License | |
| Б | documents | Wandracturing License | |
| | documents | Manufacturing License renewal /validity | |
| | | certificate | |
| | | Non Conviction Certificate issued by the | |
| | | Drugs Controller | |
| | | WHO-GMP Certificate | |
| | | Import License, if imported. | |
| | | Sale License, in the case of imported drugs | |
| | | Copy of record of import to establish 3 years | |
| | | market standing, if imported. | |
| | | Product Permissions by the Licensing | |
| | | Authority for each and every product quoted | |
| | | Market Standing Certificate issued | |
| | | by the licensing Authority | |
| | | Performance Statement | |
| | | Annexure-VI Check List Of Details Regarding | _ |
| | | Products Quoted | |
| C | Other | Documentary evidence for the constitution of | |
| | Documents | the company / concern | |
| | | The instruments such as power of attorney | |
| | | resolution of board etc | |
| | | Copies of balance sheet & profit loss | |
| | | account for three years | |
| | | Sales Tax clearance certificate | |
| | | Excise Registration Certificate | |
| | | Copy of PAN | |
| | | Annual Turnover Statement | |
| | | Annexure-VII Declaration and Undertaking | |
| | | Annexure-XI Undertaking For Empanelment | |

Check list of details regarding products quoted

Product permission as per condition no. 5 (c) and Market Standing as per condition 5 (g)

| S. No. | Quoted Item /Code no. | Product permissi on enclosed on page no. | Date of product permission / Approval | Product permission of formulation Generic / Branded | Specifica tion as per Code no. Yes/ No | produ | since | MSC fg & last 3 Date of | Statement |
|-----------|--------------------------------|--|---------------------------------------|--|--|-------|-------|--------------------------|-----------|
| 1 | | | | | | | | Issue | |
| 2 | | | | | | | | | |
| 3 | | | | | | | | | |
| 4 | | | | | | | | | |
| 5 | | | | | | | | | |

Annexure - VII

Ref. Clause No. 5 (o),(q),(r),(t),(v),(w)

Declaration & Undertaking

| (For F.02 | 2(169)/ | RMSC/PR | OCUR | EMEN' | T/DRU | JG/NIB | -01/2015/01 | Dated:01.01.20 | 16) |
|-----------|---------|------------|--------|--------|--------|--------|-------------|-----------------|----------|
| | | (On I | Non-J | udicia | l Stai | np Pa | per of Rs 3 | 500/-) | |
| I Name | e | S | /o | | | Age | Prop./ | Partner/Directo | or/Power |
| of attorr | ney ho | older of f | irm M | [/s | | | | situated at (C | Complete |
| address | of M | fg. unit). | | | | | | bear | ing drug |
| license | on | Form | 25, | 28, | 10 | etc | bearing | Number | |
| & | | | | | | .respe | ctively, | issued | on |
| dated | | v | alid/R | Lenewe | ed up | to | | do here by | declare |
| on oath | as foll | lows:- | | | | | | | |

- 1. That none of the quoted Drug and Medicines manufactured / imported by us since grant of above drug license have been found as of spurious or adulterated quality and no case in this regard is pending in any court.
- 2. That the quoted product is manufactured/imported by us, and none has been declared as "Not of standard quality" during last two years.
- 3. That we have following Commitment of quantity in our plant at above address:-[Ref. Clause No. 24]

| S. No. | Quoted item Code No. & Name of Drugs | Monthly Capacity in all shifts in nos. | Annual Production Capacity | Monthly supply Commitment to RMSC in nos. | Supply Commitment quantity during rate contract period | Estimated Bid Quantity as per Annexure VIII |
|-----------|--------------------------------------|---|----------------------------------|---|--|---|
| 1. | | | | | | |
| 2. | | | | | | |

4. That concern/company/firm does not stand blacklisted/banned/debarred on any ground by Bid Inviting Authority or Govt. of Rajasthan or its departments on the date of bid submission. The concern/company/firm does not stand blacklisted/banned/debarred on the ground of conviction by court of law or the products being found spurious or adulterated by any other State /Central Government or it's any agencies (central Drugs procurement agencies). But my firm is blacklisted/banned/debarred different on ground bv

procurement agency, the details of which are given below------(Write 'NIL' if no such matter exists)

- 5. That our Firm/Company and its Proprietor/Partner/Directors/ Power of attorney holders have not been convicted for contravention of any provisions of Drugs & Cosmetic Act 1940 and rules made there under since grant of license.
- 6. That we have been granted product permission by the State Licensing Authority for manufacture of quoted products as per the details given below:-

| S. No. | Code No. | Name of the Product | Date of product permission obtained from the Licensing Authority | Endorsement is | 0 | Own manufactur ing / Loan Licensee (Please mention) | Drug manufactur ing/Import License Number for quoted items |
|-----------|-------------|---------------------------|--|----------------|---|--|--|
| 1. | | | | | | | |
| 2. | | | | | | | |

- 7. That we have over three years' experience in the manufacture of the quoted product, or the quoted imported product has over 3 years market standing.
- 8. That we have approved qualified staff, machines & equipments along with capacity to manufacture above category of drugs and our unit have been issued **WHO-GMP*** by Licensing Authority vide letter No.......dated......valid upto......
- 9. That we hereby confirm that we have deposited all the VAT/Sale Tax as on......With the department No VAT/CST is due on M/s.....as on.....
- 10. That I will supply the Drug and Medicines per the designs given in Bid clause no 14 and as per the instructions given in this regard.
- 11. That I/We have carefully read all the conditions of Bid in Ref. no. F.02(169)/RMSC/PROCUREMENT/DRUG/NIB-01/2015/01 Dated:01.01.2016 for Rate Contract cum Supply, of Drugs and Medicines (Two year Rate Contract ending on 31.03.2018) for Rajasthan Medical Services Corporation and accept all conditions of Bid, including amendments if

any. If case of typographical error found in submitted documents / affidavits, in this case we accept all the Terms and conditions of bid documents.

- 12. I/We agree that the Bid Inviting Authority forfeiting the Bid security Deposit and or Performance Security and blacklisting /Debarring/Banning me/ us for a period of 5 years or as deemed fit if, any information furnished by us proved to be false/fabricated at the time of inspection and not complying the conditions as per Schedule M of the said Act or at any time during the Bid process.
- 13. I/ we hereby declare under Section 7 of Rajasthan Transparency in Public Procurement Act, 2012. that:
 - a. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;
 - b. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the State Government or any local authority as specified in the Bidding Document;
 - c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;
 - d. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;
 - e. I/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition.
- 14. The quoted rates of any items is not more than the price fixed by the govt. under the current drugs (Price control) order.

| 15. Our | complete | address | tor |
|----------------|----------|---------|-----|
| communication. | | | |
| | | | |
| | | | |

| Pin | |
|--|--------------------------------|
| E-mail address : - | |
| Phone No. /Mobile No. | |
| 16. Bank detail for e banking:- | |
| Name of account holder | |
| Full name of Bank with Branch | |
| Address of BankPin | |
| A/c no. with full digits | |
| IFSC code | |
| 17. Authorized/nominating person | |
| Name: | Photograph of Authorized/ |
| Designation:- | nominating person |
| E-mail address:- | Signature of |
| Phone No./Mobile No | Authorized / nominating person |
| (Name of Deponent & Sig Designation | gnature) |
| <u>Verification</u> | |
| S/o(Designation) | Affirm |
| oath that the contents/information from para 1 to 17 as mentioned above, | |
| correct to the best of my knowledge and nothing is hidden. I also declare t if any information furnished by me as above is found wrong, false, f | |
| pricated; the Corporation will be at liberty to cancel the Bid for which I | • |
| ely responsible and the firm may be Debarred/Banned/ blacklisted / prosections | cuted for |
| same. (Name of Department & Sig | matura) |
| (Name of Deponent & Sig | gnature) |
| itness :- (Name, Address & Signature) | |
| | |
| e WHO-GMP certificate must not be older than one year from the label Bid submission in case validity is not mentioned in the certain | |

Annexure – VIII Ref. Clause No. 9 (2, 3)

List of Drugs with Specifications

| C | O. 1 | Name of the small and the same | _ | | T-4! 4 1 | D |
|----------|-------------|---|---|--|---|---|
| S. No | Code No. | Name of item with specification | Packing Unit | Minimum labelled Shelf Life (In Months) | Estimated Bid Qty. for 2 year (No. of tabs, Caps, ampoules, bottles, tubes, etc.) | Requiremen t regarding label printing, layout, packing, tablet shape/colour etc |
| 1 | 2 | 3 | 4 | 6 | 7 | 8 |
| 1. | 2 | Bupivacaine Hydrochloride in Dextrose Injection USP Each ml contains Bupivacaine Hydrochloride 5.0 mg Dextrose 80.0 mg. | 4 ml Amp (10 Amp) | 24 | 347700 | |
| 2. | 6 | Halothane BP 250 ml | 250 ml in Amber coloured bottle | 36 | 5852 | |
| 3. | 8 | Ketamine Injection IP 50 mg/ ml | 10 ml Vial | 24 | 117834 | |
| 4. | 9 | Lignocaine Ointment 5% | 10 gm tube in a unit carton | 24 | 416024 | |
| 5. | 10 | Lignocaine and Adrenaline Inj. IP Each ml. Contains:- Lignocaine Hydrochloride IP 20 mg. Adrenaline IP 0.01 mg | 30 ml Vial | 12 | 209550 | |
| 6. | 13 | Lignocaine injection IP 2% | 30 ml Vial | 24 | 511750 | |
| 7. | 15 | Thiopentone Injection IP 0.5 g | Vial | 24 | 79782 | |
| 8. | 16 | Aspirin Tablets IP 300mg | 10x10 Tab strip | 24 | 6641614 | |
| 9. | 22 | Ibuprofen and Paracetamol Tablets Ibuprofen 400 mg +Paracetamol 325mg | 10x10 Tab Blister | 24 | 283334856 | |
| 10. | 26 | Paracetamol Drops [Paediatric Paracetamol Oral Suspension IP] (Each ml contains Paracetamol 150 mg) | 15 ml Bottle (with a separate dropper, which should be able to screw & cap the bottle) in a unit carton | 24 | 7503692 | |
| 11. | 30 | Pentazocine Injection IP 30mg/ml (IM/IV Use) | 1 ml Amp (25 ampoules) | 24 | 1392526 | |
| 12. | 32 | Tramadol Capsules IP 50 mg | 10x10 Cap strip/Blister | 36 | 23666960 | |
| 13. | 39 | Dexamethasone Injection IP 8 mg/2ml | 2 ml Vial (USP Type I vial) | 18 | 12424198 | |
| 14. | 42 | Hydrocortisone Sod. Succinate Injection IP 100 mg base / vial (IM/IV use) | Vial | 36 | 2970292 | |

| S. No | Code No. | Name of item with specification | Packing Unit | Minimum labelled Shelf Life (In Months) | Estimated Bid Qty. for 2 year (No. of tabs, Caps, ampoules, bottles, tubes, etc.) | Requiremen t regarding label printing, layout, packing, tablet shape/colour etc |
|----------|-------------|---|--|--|---|---|
| 1 | 2 | 3 | 4 | 6 | 7 | 8 |
| 15. | 44 | Methyl Prednisolone Sodium Succinate for Injection USP 500 mg | Vial | 36 | 283870 | |
| 16. | 45 | Pheniramine Injection IP 22.75mg/ml | 2 ml Amp (25 ampoules) | 36 | 5338422 | |
| 17. | 47 | Prednisolone Tablets IP 5 mg | 10x10 Tab strip/blister | 24 | 21456168 | |
| 18. | 50 | Promethazine Tablets IP 25 mg | 10 x 10 Tab Strip | 36 | 4233864 | |
| 19. | 51 | Naloxone Injection IP 0.4mg/ ml | 1ml Amp (10 ampoules) | 24 | 12376 | |
| 20. | 54 | Carbamazepine Tablets IP 100 mg (Film Coated) | 10x10 Tab strip/Blister | 36 | 3757444 | |
| 21. | 57 | Phenytoin Injection 50mg/ml | 2 ml Amp Amber Colour (25 Amp) | 36 | 1682414 | |
| 22. | 58 | Phenytoin Oral suspension IP 25mg/ml | 100 ml Glass bottle with measuring cap | 24 | 37962 | |
| 23. | 60 | Sodium Valproate IP Injection 100 mg/ ml | Vial | 36 | 141256 | |
| 24. | 62 | Acyclovir oral Suspension IP 400mg/5ml | 60 ml Bottle with measuring cap | 24 | 67506 | |
| 25. | 64 | Acyclovir Tablets IP 800 mg | 10x10 Tab strip | 36 | 4037080 | |
| 26. | 65 | Albendazole Oral suspension IP 400 mg/10ml | 10 ml Bottle | 24 | 5997142 | |
| 27. | 71 | Amoxycillin Capsules IP 250mg | 10x10 Cap strip/ blister | 24 | 82455082 | |
| 28. | 72 | Amoxycillin Capsules IP 500mg | 10x10 Cap strip/ blister | 24 | 155132772 | |
| 29. | 73 | Amoxycillin Dispersible Tablets IP 125mg | 10 x 10 Tab strip | 24 | 39582514 | |
| 30. | 74 | Amphotericin B Injection IP 50 | Vial | 24 | 3150 | |
| 31. | 98 | Chloroquine Phosphate Injection IP 40mg/ml | 5 ml Amp (25 ampoules) | 24 | 2277440 | |
| 32. | 100A | Chloroquine Phosphate Suspension IP 50 mg/5ml | 60 ml bottle with measuring cap | 30 | 1961938 | |
| 33. | 101 | Ciprofloxacin Injection IP 200mg/100ml | 100ml FFS/ BFS Bottle | 24 | 3198836 | |

| S. No | Code No. | Name of item with specification | Packing Unit | Minimum labelled Shelf Life (In Months) | Estimated Bid Qty. for 2 year (No. of tabs, Caps, ampoules, bottles, tubes, etc.) | Requiremen t regarding label printing, layout, packing, tablet shape/colour etc |
|----------|-------------|---|---|--|---|---|
| 1 | 2 | 3 | 4 | 6 | 7 | 8 |
| 34. | 108 | Co-trimoxazole Tablets IP Trimethoprim 40 mg and Sulphamethoxazole 200 mg | 10x10 Tab Blister | 36 | 39598418 | |
| 35. | 109 | Co-trimoxazole Tablets IP Trimethoprim 80 mg and Sulphamethoxazole 400 mg | 10 x 10 Tab Blister | 36 | 85965766 | |
| 36. | 110 | Diethylcarbamazine Tablets IP 100 mg | 10x10 Tab Blister | 36 | 484372 | |
| 37. | 114A | Fluconazole Tab. IP150mg. | 10x10x1 Tab strip | 24 | 8567782 | |
| 38. | 116 | Gentamicin Injection IP 80mg/2ml (IM/ IV use) | 2 ml amp (50 Ampoules) | 24 | 9990658 | |
| 39. | 117 | Griseofulvin Tablet 125 mg | 10 x 10 Tab Strip | 36 | 2131666 | |
| 40. | 119 | Meropenem Injection IP 500 mg | Vial | 24 | 288018 | |
| 41. | 120 | Metronidazole Injection IP 500 mg/100ml | 100ml FFS/ BFS Bottle | 36 | 6543662 | |
| 42. | 121 | Metronidazole Benzoate Oral Suspension IP 100 mg of base/5ml | 60 ml bottle (Amber colour) with measuring Cap | 36 | 6056220 | |
| 43. | 124 | Norfloxacin Tablets IP 400 mg Film Coated | 10 x 10 Tab Blister | 36 | 43058766 | |
| 44. | 132 | Quinine sulphate Tablets IP 300mg (Film Coated) | 10 x10 Tab Blister | 24 | 3769970 | |
| 45. | 136 | Chlorambucil Tablets IP 5 mg | 30 Tablets Bottle | 24 | 17780 | |
| 46. | 140 | Cyclosporin Capsules IP 25mg | 50 Caps pack | 24 | 730400 | |
| 47. | 143 | Daunorubicin Injection IP 20 mg | 10 ml glass vial | 24 | 5440 | |
| 48. | 144 | Doxorubicin Injection IP 50 mg/ 25 ml | vial | 24 | 45970 | |
| 49. | 148 | Fluorouracil Injection IP 250 mg/ 5ml | 5 ml Ampoule | 24 | 161700 | |
| 50. | 152 | Mercaptopurine Tablets IP 50 mg | 10 x 10 Tab strip | 24 | 53800 | |
| 51. | 156 | Paclitaxel Injection IP 100 mg | 16.7 ml vial | 24 | 34000 | |
| 52. | 158 | Vinblastine Injection IP 10mg | Vial | 24 | 1960 | |
| 53. | 161 | Levodopa 250mg and Carbidopa 25 mg Tab IP | 10 x10 Tab strip | 24 | 336600 | |
| 54. | 162 | Trihexyphenidyl Hydrochloride Tablets IP 2 mg | 10 x10 Tab Blister | 36 | 12011610 | |

| S. No | Code No. | Name of item with specification | Packing Unit | Minimum labelled Shelf Life (In Months) | Estimated Bid Qty. for 2 year (No. of tabs, Caps, ampoules, bottles, tubes, etc.) | Requiremen t regarding label printing, layout, packing, tablet shape/colour etc |
|----------|-------------|--|---|--|---|---|
| 1 | 2 | 3 | 4 | 6 | 7 | 8 |
| 55. | 166 | Deferasirox Tablets 500 mg | 30 Tab | 24 | 488660 | |
| 56. | 167 | Deferiprone Capsules 250 mg | 50 Caps | 24 | 34000 | |
| 57. | 168 | Deferiprone Capsules 500 mg | 50 Caps | 24 | 362200 | |
| 58. | 169 | Desferrioxamine Injection IP 500 mg / Vial (For I.M. Inj and I.V., S.C. Infusion) | Vial | 24 | 47860 | |
| 59. | 172 | Enoxaparin Sodium Injection IP 60 mg | Vial / PFS | 24 | 511698 | |
| 60. | 175 | Human Albumin Solution IP 20% | 100 ml Bottle | 24 | 83688 | |
| 61. | 179 | Rh-Erythropoetin Injection 4000 IU | Vial / PFS | 24 | 68800 | |
| 62. | 185 | Amlodipine Tablets IP 5 mg | 10x10 Tab Blister | 36 | 69969404 | |
| 63. | 195 | Enalapril Maleate Tablets IP 2.5mg | 10 x 10 Tab Strip | 24 | 2244760 | Name of drug in black colour and rest details in red colour on strip |
| 64. | 198 | Isosorbide mononitrate Tabs IP 20 mg | 10 x 10 Tab Strip | 24 | 13110740 | Name of drug & Logo to be printed in Indigo and rest details in red colour on strip |
| 65. | 204 | Nifedipine Tablets IP 10 mg.(Sustained Release) | 10x10 Tab Blister | 36 | 2550008 | T. I |
| 66. | 209 | Streptokinase Injection 15 lac units | Vial | 24 | 22572 | |
| 67. | 211 | Verapamil Tablets IP 40 mg (Film Coated) | 10x10 Tab Strip | 30 | 317380 | |
| 68. | 212 | Verapamil Injection IP 2.5 mg/ml | 2 ml Amp (25 Amp) | 24 | 29652 | |
| 69. | 215A | Cetrimide Cream IP | 15 gm Tube in unit carton | 24 | 2014694 | |
| 70. | 220 | Miconazole Nitrate Cream IP 2% | 15 gm tube in unit carton | 24 | 4218670 | |
| 71. | 223 | Powder Neomycin Bacitracin with Sulphacetamide (Neomycin 5mg, Bacitracin 250 units, Sulphacetamide 60 mg) | 10 gm Plastic Bottle with Nozzle to sprinkle powder | 18 | 2458460 | |

| S. No | Code No. | Name of item with specification | Packing Unit | Minimum labelled Shelf Life (In Months) | Estimated Bid Qty. for 2 year (No. of tabs, Caps, ampoules, bottles, tubes, etc.) | Requiremen t regarding label printing, layout, packing, tablet shape/colour etc |
|----------|-------------|--|---|--|---|---|
| 1 | 2 | 3 | 4 | 6 | 7 | 8 |
| 72. | 225 | Anti A Blood Grouping Serum IP (Anti A Monoclonal Serum) | 10 ml Vial | 12 | 64548 | |
| 73. | 226 | Anti B Blood Grouping Serum IP (Anti B Monoclonal Serum) | 10 ml Vial | 12 | 64394 | |
| 74. | 227 | Anti DRH Blood Grouping Serum IP | 10 ml Vial | 12 | 66704 | |
| 75. | 229 | Barium Sulphate Suspension IP 100% | 500 ml | 24 | 4254 | |
| 76. | 231 | Diagnostic Sticks for Urine Sugar | 50's Pack | 18 | 781546 | |
| 77. | 232 | Diatrizoate Meglumine and Diatrizoate Sodium Inj USP 60% (iodine conc = 292 mg/ml) | 20 ml Amp | 36 | 1720 | |
| 78. | 233 | Diatrizoate Meglumine and Diatrizoate Sodium Inj USP 76% w/v (iodine conc =370 mg/ml) | 20 ml Amp | 36 | 8880 | |
| 79. | 236 | Iohexol USP (Solution for Injection) Non Ionic contrast medium in Sterile aqueous solution 300 mg Iodine/ml. | 50 ml Pack | 30 | 195050 | |
| 80. | 241 | Tropicamide Eye Drops IP 1% | 5 ml Vial with sterilized dropper, or squeeze vial | 24 | 74258 | |
| 81. | 244 | Compound Benzoin Tincture IP | 500 ml Bottle | 30 | 65936 | |
| 82. | 246 | Gentian Violet Topical Solution USP 1% | 200 ml Bottle | 24 | 150778 | |
| 83. | 247 | Gluteraldehyde solution 2 % | 5 Ltrs Can | 18 | 30102 | |
| 84. | 248 | Hydrogen Peroxide Solution IP 6% (20 Vol) | 400 ml Bottle with Inner Cap | 24 | 297448 | |
| 85. | 252 | Surgical Spirit IP/BP | 500 ml Opaque white colour bottle with Inner Cap | 36 | 398256 | |
| 86. | 253 | Acetazolamide Tablets IP 250mg | 10 x 10 Tab Blister | 36 | 718740 | |
| 87. | 255 | Furosemide Injection IP 10mg/ml (IM & IV use) | 2 ml Amp | 24 | 2292282 | |
| 88. | 256 | Hydrochlorthiazide Tablets IP 12.5 mg | 10x10 Tab strip | 24 | 5868166 | |

| S. No | Code No. | Name of item with specification | Packing Unit | Minimum labelled Shelf Life (In Months) | Estimated Bid Qty. for 2 year (No. of tabs, Caps, ampoules, bottles, tubes, etc.) | Requiremen t regarding label printing, layout, packing, tablet shape/colour etc |
|----------|-------------|--|---|--|---|---|
| 1 | 2 | 3 | 4 | 6 | 7 | 8 |
| 89. | 257A | Mannitol Injection IP 20% w/v | 100 ml FFS/BFSBottle | 24 | 471124 | |
| 90. | 264 | Dicyclomine Injection IP 10 mg/ml | 2 ml Amp (25 ampoules) | 24 | 5795356 | |
| 91. | 270 | Metoclopramide Injection IP 10mg/2ml | 2 ml Amp (Amber colour) (25 ampoules) | 24 | 9423634 | |
| 92. | 273 | Ondansetron Injection IP 2mg/ml | 2 ml Amp (10 ampoules) | 36 | 8880506 | |
| 93. | 278 | Sodium Phosphates Enema BP Each 100ml contains Sodium Dihydrogen phosphate Dihydrate 10%, Disodium Hydrogen Phosphate Dodecahydrate 8% | 100 ml polypropylene pack | 24 | 1412360 | |
| 94. | 279 | Biphasic Isophane Insulin Injection IP(30% Soluble Insulin & 70% Isophane Insulin) Inj 40 IU/ml (r-DNA origin) | 10 ml Vial | 24 | 1630126 | |
| 95. | 280 | Carbimazole Tabs IP 5 mg (Film Coated) | 10x10 Tab Blister | 24 | 548600 | |
| 96. | 281 | Carboprost Tromethamine Injection Each ml contains Carboprost 0.25mg/ml | 1 ml Amp/Vial (25 Ampoules/Vial | 24 | 158440 | |
| 97. | 282 | Clomifene Tablets IP 25 mg | 10 x10 Tab strip | 24 | 83400 | |
| 98. | 284 | Conjugated Estrogen Tabs USP 0.625 mg. | 10x10 Tab or 1x28 Tab Strip/Blister (Rate should be quoted for one Tablet) | 36 | 148920 | |
| 99. | 285 | Dinoprostone Cream/Gel 0.5 mg Dinoprostone in syringe | Pre - Filled Syringe | 24 | 184112 | |
| 100. | 286 | Ethinyloestradiol Tabs IP 50 mcg | 10x10 Tab Strip | 24 | 130700 | |
| 101. | 294 | Isophane Insulin Injection IP 40 IU/ml | 10 ml Vial | 24 | 136396 | |
| 102. | 296 | Norethisterone Tablets IP 5 mg | 10x10 Tab strip | 24 | 2065738 | |

| S. No | Code No. | Name of item with specification | Packing Unit | Minimum labelled Shelf Life (In Months) | Estimated Bid Qty. for 2 year (No. of tabs, Caps, ampoules, bottles, tubes, etc.) | Requiremen t regarding label printing, layout, packing, tablet shape/colour etc |
|----------|-------------|--|--|--|---|---|
| 1 | 2 | 3 | 4 | 6 | 7 | 8 |
| 103. | 300 | Insulin Injection IP (Soluble Insulin / Neutral Insulin Injection) 40 IU/ ml. (r-DNA origin) | 10 ml Vial | 24 | 229170 | |
| 104. | 301 | Thyroxine Sodium Tablets IP 100mcg | 10x10 Tab strip | 24 | 6464762 | |
| 105. | 303 | Human Anti D Immunoglobulin Injection 300mcg (I.M.use) | Pre-filled Syringe/Vial | 24 | 72662 | |
| 106. | 306 | Rabies Vaccine Human (Cell Culture) IP (Intradermal) 2.5 IU | 1 ml vial with 1.0 ml diluent | 36 | 876344 | |
| 107. | 309 | Tetanus Immunoglobulin 250 IU/ Vial | Vial | 36 | 33684 | |
| 108. | 310 | Tetanus Vaccine (adsorbed) I.P. | 5 ml Vial | 36 | 2099194 | |
| 109. | 316 | Neostigmine Tablets IP 15 mg | 10x10 Tab Strip | 24 | 40682 | |
| 110. | 319 | Atropine Eye Ointment IP 1% | 3 gm Tube in Unit Carton | 24 | 29982 | |
| 111. | 320 | Atropine Sulphate Ophthalmic Solution USP 1% | 5ml vial with sterilized dropper, or squeeze vial | 24 | 43602 | |
| 112. | 324 | Hydroxypropylmethyl cellulose Solution 20 mg/ ml | 2 ml Glass Syringe (With Cannula) | 24 | 76506 | |
| 113. | 326 | Pilocarpine Eye Drops IP 2% | 5ml squeeze vial | 24 | 31154 | |
| 114. | 334 | Isoxsuprine Tablets IP 20 mg | 10x10 Tab Strip | 36 | 1868342 | |
| 115. | 338 | Oxytocin Injection IP 5 IU/ml | 1 ml Amp (Single Unit in Blister pack) | 24 | 8940120 | |
| 116. | 343 | Chlorpromazine Tablets IP 100 mg (Coated Tablet) | 10x10 Tab strip | 24 | 1269316 | |
| 117. | 344 | Chlorpromazine Tablets IP 25 mg (Sugar- Coated) | 10 x10 Tab Strip | 36 | 915732 | |
| 118. | 345 | Chlorpromazine Tabs IP 50 mg. (Coated Tablets) | 10x10 Tab Strip | 36 | 1065844 | |
| 119. | 347 | Clomipramine Capsules IP 25 mg | 10x10 Cap Strip | 24 | 508204 | |
| 120. | 355 | Haloperidol Tablets IP 5 mg | 10x10 Tab strip | 24 | 2005460 | |
| 121. | 357 | Imipramine Tablets IP 75 mg (Coated) | 10x10 Tab Blister | 36 | 635250 | |

| S. No | Code No. | Name of item with specification | Packing Unit | Minimum labelled Shelf Life (In Months) | Estimated Bid Qty. for 2 year (No. of tabs, Caps, ampoules, bottles, tubes, etc.) | Requiremen t regarding label printing, layout, packing, tablet shape/colour etc |
|----------|-------------|--|--|--|---|---|
| 1 | 2 | 3 | 4 | 6 | 7 | 8 |
| 122. | 365 | Aminophylline Injection IP 25 mg/ml | 10 ml Amp (25 Ampoules) | 24 | 401040 | |
| 123. | 368 | Cough Syrup Each 5ml contains Chloropheniramine Maleate IP 3mg Ammonium Chloride 130mg, Sodium Citrate 65 mg, Menthol 0.5 mg, Syrup Q.S. | 50 ml Bottle with Measuring Cap | 24 | 52370544 | |
| 124. | 369 | Ipratropium Bromide Nebulizer Solution 250 mcg/ ml | 15 ml Glass Bottle | 36 | 273408 | |
| 125. | 371 | Salbutamol Inhalation 100 mcg /dose | 200 metered dose container | 36 | 1999036 | |
| 126. | 376 | Theophylline Tablets 400 mg Sustained release/controlled release (Theophylline prolonged Release Tablets IP) | 10x10 Tab Blister | 24 | 4924276 | |
| 127. | 377 | Compound Sodium Lactate inj. IP | 500 ml FFS/BFS Bottle | 36 | 13099982 | |
| 128. | 378 | Dextrose Injection IP 25 % w/v | 100 ml FFS/BFS bottle | 36 | 1488426 | |
| 129. | 379 | Dextrose injection IP 10% | 500 ml FFS/BFS Bottle | 36 | 2132262 | |
| 130. | 380 | Dextrose injection IP 5% | 500 ml FFS/BFS Bottle | 36 | 10306654 | |
| 131. | 381 | Multiple Electrolytes & Dextrose Injection Type I IP (Electrolyte 'P' Injection) | 500 ml FFS / BFS Bottle | 36 | 1574424 | |
| 132. | 382 | Multiple Electrolytes & Dextrose Injection Type III IP Electroylte "M" Injection (I.V.) | 500 ml FFS / BFS Bottle | 36 | 415524 | |
| 133. | 383 | Potassium Chloride Injection 0.15 gm/ml | 10 ml Amp (10 ampoules) | 24 | 340158 | |
| 134. | 384 | Potassium chloride Oral Solution U.S.P 500mg/ 5ml | 200 ml Bottle (Amber colour) with Measuring Cap | 36 | 34288 | |
| 135. | 385 | Sodium Chloride and Dextrose Inj. I.P (0.9%+5%) | 500 ml FFS/BFS Bottle | 36 | 9660852 | |

| S. No | Code No. | Name of item with specification | Packing Unit | Minimum labelled Shelf Life (In Months) | Estimated Bid Qty. for 2 year (No. of tabs, Caps, ampoules, bottles, tubes, etc.) | Requiremen t regarding label printing, layout, packing, tablet shape/colour etc |
|----------|-------------|---|---|--|---|---|
| 1 | 2 | 3 | 4 | 6 | 7 | 8 |
| 136. | 386 | Sodium Chloride Injection IP | 500 ml FFS/BFS Bottle | 36 | 6165106 | |
| 137. | 397 | Vitamin – B complex tablet NFI(prophylactic) B1- 2mg, B2- 2mg, B6-0.5mg, Niacinamide 25mg, Calcium pantothenate 1mg (With appropriate overages) | 10 x 10 Tab Strip/ blister | 24 | 204541524 | |
| 138. | 398 | Black Disinfectant Fluid (Phenyl) (As per Schedule "O" Grade – III | 5 Lit Can | 18 | 193580 | |
| 139. | 399 | Concentrated Solution for Haemodialysis B.P Acetate concentrate in 10 Litre Cans. | 10 Ltrs Plastic Can | 24 | 24220 | |
| 140. | 401 | Peritonial Dialysis Solution IP | 1000 ml FFS/ BFS Pack | 24 | 491050 | |
| 141. | 402 | Sodium Bicarbonate Injection IP 7.5% w/v | 10 ml Amp (25 Ampoules) | 24 | 893372 | |
| 142. | 404 | Water for injection I.P. | 10 ml Amp 50 amp. | 36 | 30652890 | |
| 143. | 408 | Rabies Antiserum IP (Equine) 300 units per ml [contains equine anti-rabies immunoglobulin fragments](I.M./SC use) | 5 ml Vial | 24 | 75158 | |
| 144. | 409 | Vitamin A Paediatric oral solution IP Vitamin A Concentrate Oil IP Each ml contains vitamin A 100000 IU | 100 ml bottle and spoon with marking 1ml/2ml in unit carton | 18 | 668998 | |
| 145. | 412 | Ampicillin Capsules IP 500 mg | 10 x 10 Cap Blister | 24 | 21567612 | |
| 146. | 416 | Hydroxyethyl Starch (130/0.4) 6% w/v with Sodium Chloride 0.9% w/v Intravenous Infusion | 500 ml plastic bottle | 36 | 132800 | |
| 147. | 417 | Cloxacillin sodium Injection IP 500 mg | Vial | 24 | 66300 | |
| 148. | 420 | Phenobarbitone Injection IP 200mg/ml | 1 ml ampoule/vial | 24 | 128220 | |
| 149. | 421 | Flurbiprofen Sodium Ophthalmic Solution IP 0.03% w/v | 5 ml squeeze vial | 24 | 229096 | |

| S. No | Code No. | Name of item with specification | Packing Unit | Minimum labelled Shelf Life (In Months) | Estimated Bid Qty. for 2 year (No. of tabs, Caps, ampoules, bottles, tubes, etc.) | Requiremen t regarding label printing, layout, packing, tablet shape/colour etc |
|----------|-------------|--|---|--|---|---|
| 1 | 2 | 3 | 4 | 6 | 7 | 8 |
| 150. | 423 | Hyaluronidase Injection IP Each vial contains Hyaluronidase IP 1500 I.U. | Vial | 24 | 17064 | |
| 151. | 424 | Lidocaine Hydrochloride Topical Solution USP 4% | 30 ml Vial | 36 | 21232 | |
| 152. | 428 | Ofloxacin Oral Suspension IP 50mg/5ml | 30 ml bottle | 24 | 3006672 | |
| 153. | 434 | Famotidine Tablets IP 20 mg | 10 x 14 Tab Blister | 36 | 6761186 | |
| 154. | 435 | Famotidine Tablets IP 40 mg | 10 x 14 Tab Blister | 36 | 7262136 | |
| 155. | 436 | Indomethacin Capsules IP 25 mg | 10x10 Cap Strip | 36 | 1683122 | |
| 156. | 437 | Diclofenac Prolonged Release Tablete IP | 10x10 Tab strip | 36 | 20972744 | |
| 157. | 444 | Aspirin Delayed Release Tablets / Aspirin Gastroresistant Tablets. Each enteric coated tablet contains Acetyl Salicylic Acid 75 mg | 10 x 14 Tablets Strip | 24 | 23114484 | |
| 158. | 449 | Surgical Spirit IP/BP | 100 ml Opaque white colour bottle with Inner Cap | 24 | 1621878 | |
| 159. | 453 | Glibenclamide and Metformin Hydrochloride (SR) Tablets [Glibenclamide 5mg, Metformin Hydrochloride 500 mg (Sustained Release)] | 10 x 10 Tab Blister | 24 | 2976040 | |
| 160. | 454 | Metformin Hydrochloride (Sustained Release) and Glimperiride Tablets {Metformin Hydrochloride (Sustained Release) 500 mg, Glimipiride 1 mg} | 10 x 10 Tab Blister | 36 | 11519182 | |
| 161. | 457 | Amlodipine and Enalapril Maleate Tablet (Amlodipine Besilate equivalent to Amlodipine 5mg, Enalapril maleate 5mg) | 10 x 10 Tab Strip | 24 | 1994020 | |

| S. No | Code No. | Name of item with specification | Packing Unit | Minimum labelled Shelf Life (In Months) | Estimated Bid Qty. for 2 year (No. of tabs, Caps, ampoules, bottles, tubes, etc.) | Requiremen t regarding label printing, layout, packing, tablet shape/colour etc |
|----------|-------------|--|--|--|---|---|
| 1 | 2 | 3 | 4 | 6 | 7 | 8 |
| 162. | 458 | Losarton Potassium & Amlodipine tablets IP (Losarton Potassium 50 mg, Amlodipine Besilate eq. to Amlopdipine 5mg) | 10 x 10 Tab Strip/Blister | 36 | 8877402 | |
| 163. | 459 | Losarton Potassium & Hydrochlorothiazide Tablets IP (Losarton Potassium 50 mg, Hydrochlorothiazide 12.5 mg) | 10 x 10 Tab Blister | 36 | 18603988 | |
| 164. | 461 | Amlodipine and AtenololTablets [Amlodipine Besilate equivalent to Amlodipine 5 mg, Atenolol 50mg] | 10 x 10 Tab Blister | 36 | 25892152 | |
| 165. | 463 | Enalapril Maleate Tablets IP 10 mg | 10 x 10 Tab strip | 36 | 3295548 | |
| 166. | 464 | Hydrochlorothiazide Tablets IP 25 mg | 10x10 Tab strip | 36 | 808606 | Name of drug to be printed in red colour and rest details in blue colour on strip. |
| 167. | 465 | Lisinopril Tablets IP 10 mg | 10 x 10 Tab Strip/Blister | 24 | 687588 | |
| 168. | 469 | Prednisolone Tablets IP 10 mg | 10 x 10 Tab strip/Blister | 24 | 22150260 | |
| 169. | 474 | Carbamazepine Oral Suspension USP 100 mg/5ml | 100 ml Bottle with measuring Cap | 24 | 23392 | |
| 170. | 477 | Ibuprofen Oral Suspension BP/USP 100 mg/ 5 ml | 60 ml Bottle with measuring Cap | 36 | 5830474 | |
| 171. | 484 | Timolol Eye Drops IP 0.5% w/v | 5 ml squeeze vial | 24 | 71974 | |
| 172. | 485 | Homatropine Eye Drops IP 2 % | 5 ml squeeze Vial | 24 | 37576 | |
| 173. | 493 | Diclofenac Gel: Diclofenac Diethylamine 1.16%, Methyl salicylate 10%, Linseed oil 3% and Menthol 5% | 20 gm Tube in unit Carton | 24 | 36798202 | |
| 174. | 503 | Acyclovir Intravenous Infusion IP 500 mg | Vial | 24 | 28020 | |

| S. No | Code No. | Name of item with specification | Packing Unit | Minimum labelled Shelf Life (In Months) | Estimated Bid Qty. for 2 year (No. of tabs, Caps, ampoules, bottles, tubes, etc.) | Requiremen t regarding label printing, layout, packing, tablet shape/colour etc |
|----------|-------------|--|--|--|---|---|
| 1 | 2 | 3 | 4 | 6 | 7 | 8 |
| 175. | 509 | Aztreonam Injection USP 500 mg | Vial | 24 | 76700 | |
| 176. | 518 | Mefloquine Tablets IP 250 mg | 10x6 Tablet Blister | 24 | 35400 | |
| 177. | 520 | Ofloxacin and Ornidazole Tablets (Ofloxacin 200 mg and Ornidazole 500 mg) | 10x10 Tablet Blister | 24 | 22211166 | |
| 178. | 522 | Pyrimethamine and Sulphadoxine Tablets IP (Pyrimethamine 37.5 mg and Sulphadoxine 750 mg) | 2 Tablet Strip/ Blister (50 x 2 Tab) | 24 | 13580 | |
| 179. | 526 | Carboplatin Injection 150 mg | 15 ml Vial | 24 | 11558 | |
| 180. | 536 | Methotrexate Tablets IP 10 mg | 10x10 Tablet Strip | 24 | 263640 | |
| 181. | 537 | Mitomycine Injection IP 10 mg / Mitomycine for Injection USP 10 mg | Vial | 24 | 1180 | |
| 182. | 538 | Oxaliplatin Injection USP 50 mg | 25 ml Vial | 24 | 19340 | |
| 183. | 539 | Bromocriptine Tablets IP 1.25 mg | 10x10 or 5x10 Tablet Strip (Rate should be quoted for 10 Tablet only) | 24 | 20600 | |
| 184. | 546 | Warfarin Sodium Tablets IP 5 mg | 10x10 Tablet | 24 | 227362 | |
| 185. | 551 | Isoprenaline Injection IP 2mg / ml | 1 ml Ampoule (5 Amp) | 24 | 10090 | |
| 186. | 557 | Urokinase Injection 5 Lac Unit (Lyophilized) | Vial | 24 | 12510 | |
| 187. | 558 | Betamethasone Dipropionate Cream IP 0.05% | 15 gm Tube in unit carton | 24 | 1939658 | |
| 188. | 559 | Betamethasone Lotion IP 0.05% | 50 ml | 24 | 443942 | |
| 189. | 567 | Permethrin Lotion 1% | 30 ml | 24 | 186036 | |
| 190. | 568 | Permethrin Lotion 5% | 30 ml | 24 | 414592 | |
| 191. | 571 | Povidone Iodine Ointment USP 5% | 250 gm Pack | 24 | 438392 | |
| 192. | 574 | Spironolactone Tablets IP 50 mg | 10x10 Tablet | 24 | 1830610 | |
| 193. | 575 | Finasteride Tablets IP 5 mg | 10x10 Tablet strip/ blister | 24 | 141000 | |
| 194. | 577 | Terazosin Tablets USP 1 mg | 10x10 Tablet | 24 | 13000 | |
| 195. | 578 | Terazosin Tablets USP 2 mg | 10x10 Tablet | 24 | 7600 | |
| 196. | 582 | Tooth Gel: Sodium Monofluorophosphate 0.7% and Potassium Nitrate 5% (in flavoured base) | 50 gm Tube in unit carton | 24 | 1571070 | |

| S. No | Code No. | Name of item with specification | Packing Unit | Minimum labelled Shelf Life (In Months) | Estimated Bid Qty. for 2 year (No. of tabs, Caps, ampoules, bottles, tubes, etc.) | Requiremen t regarding label printing, layout, packing, tablet shape/colour etc |
|----------|-------------|--|--|--|---|---|
| 1 | 2 | 3 | 4 | 6 | 7 | 8 |
| 197. | 583 | Gum Paint containg Tannic acid 2%, Cetrimide 0.1%, Zinc Chloride 1% | 15 ml Squeeze Vial | 24 | 544094 | |
| 198. | 584 | Metronidazole 1% and Chlorhexidine gluconate 0.25% Gel | 10 gm Tube in unit Carton | 24 | 556540 | |
| 199. | 586 | Clotrimazole 1% with Beclomethasone Dipropionate 0.025% Ear Drops | 5 ml ear drops | 24 | 286848 | |
| 200. | 587 | Clotrimazole 1% with lignocaine 1% Ear Drops | 5 ml Squeeze Vial | 24 | 1013532 | |
| 201. | 589 | Ceruminolytic Drops (Wax dissolving ear drops): Paradichlorobenzene 2%, Benzocaine 2.7%, Chlorbutol 5%, Turpentine oil 15% | 10 ml Bottle / Vial (with a separate dropper, which should be able to screw & cap the bottle) in a unit carton | 24 | 912690 | |
| 202. | 592 | Lactic Acid Bacillus Tablets 60 million spores | 10x10 Tablet | 24 | 40945112 | |
| 203. | 599 | Hydroxychloroquine Sulphate Tablets 200 mg | 10x10 Tablet | 24 | 941600 | |
| 204. | 602 | Sulfasalazine Delayed Release Tablets USP/ Gastroresistant Sulfasalazine Tablets BP 500 mg | 10x10 Tablet | 24 | 184000 | |
| 205. | 604 | Glucagon for Injection USP 1 mg | Vial | 24 | 960 | |
| 206. | 605 | Medroxyprogesterone acetate Tablets IP 10 mg | 10x10 Tablet | 24 | 166702 | |
| 207. | 606 | Testosterone Propionate Injection IP 25 mg/ 1ml | 1 ml Vial | 24 | 2800 | |
| 208. | 609 | Chlorzoxazone Tablets 250 mg | 10x10 Tablet | 24 | 1294722 | |
| 209. | 612 | Betaxolol Eye Drops 0.5% | 5 ml Squeeze Vial | 24 | 3000 | |
| 210. | 614 | Phenylephrine Hydrochloride Ophthalmic Solution USP/ Phenylephrine Eye Drops BP 5% | 5 ml Squeeze vial | 24 | 33852 | |
| 211. | 616 | Formoterol Fumerate and Budesonide Powder for Inhalation IP 6 mcg + 200 mcg | 30 Capsule (rotacaps) | 24 | 4839300 | |
| 212. | 617 | Budesonide Powder for Inhalation 200 mcg | 30 Capsule (rotacaps) | 24 | 917064 | |

| S. No | Code No. | Name of item with specification | Packing Unit | Minimum labelled Shelf Life (In Months) | Estimated Bid Qty. for 2 year (No. of tabs, Caps, ampoules, bottles, tubes, etc.) | Requiremen t regarding label printing, layout, packing, tablet shape/colour etc |
|----------|-------------|--|-----------------------------|--|---|---|
| 1 | 2 | 3 | 4 | 6 | 7 | 8 |
| 213. | 618 | Ipratropium Powder for | 30 Capsule | 24 | 604684 | |
| | | Inhalation IP 40 mcg | (Rotacaps) | | | |
| 214. | 619 | Terbutaline Tablets IP 2.5 mg | 10x10 Tablet | 24 | 599748 | |
| 215. | 622 | Calcium with Vitamin D Tablets USP/ Calcium and Colecalciferol Tablets BP (Elemental Calcium 500 mg, Vitamin D3- 250 IU)(Non- Chewable) | 10x10 Tablet | 24 | 156707400 | |
| 216. | 623 | Cholecalciferol granules 60, 000 IU/ gm | 1 gm sachet (50 Sachets) | 24 | 614340 | |
| 217. | 624 | Mecobalamin Injection 500 mcg/ml | 1 ml Ampoule | 24 | 105800 | |
| 218. | 625 | Nicotinamide Tablets IP 50 mg | 10x10 Tablet | 24 | 59700 | |
| 219. | 627 | Pyridoxine Tablets IP 40 mg | 10x10 Tablet Strip | 36 | 360392 | |
| 220. | 628 | Riboflavin Tablets IP 5 mg | 10x10 Tablet Strip | 36 | 335546 | |
| 221. | 632 | Mannitol with Glycerin Injection 10% +10% w/v (For Intravenous Infusion) | 100 ml FFS/BFS Bottle | 24 | 123640 | |
| 222. | 650 | Glyceryl Trinitrate Tablets 2.6 mg Controlled Release tablets | 30 Tablet Bottle | 24 | 516344 | |

Note:-

The above quantity mentioned for this supply cum rate contract is indicative and may vary as per the actual requirement of hospitals.

The bidder should quote rate for the above mentioned packing unit only.

General Requirement:-

- 1. The manufacturer should ensure Stability of the formulations and its ingredients in the packing supplied.
- 2. The blister packing of tablets/Capsules should have Aluminium foil back.
- 3. Strip packing should be of Aluminium / Alu- Alu foils.
- 4. Aluminium foil strips refer to thickness not less than 40 microns.
- 5. The rigid PVC used in blister packing should be of not less than 250 microns.
- 6. Small tablets packed in blister should be packed to facilitate easy removal of a tablet without breaking/crushing.
- 7. Containers for 400 ml (or 400 gm) or more, should have an inner lid also.
- 8. Syrup and Suspension should be palatable enough.
- 9. The measuring cap / dropper supplied with oral liquid formulation should have suitable marking.
- 10. The minimum size (length x breadth) of a blister strip shall be 6.5cm X 3cm.
- 11. Generic name of a drug should be printed in clearly legible bold letters. The font size of the name of drug on any tablet strip/ blister shall not be less than '9' in bold capital letters of Times New Roman or Arial font, e.g., LOSARTAN TABLETS IP even on small strips/ blisters. The font size shall be correspondingly bigger on bigger strips / blisters. Besides this, other contents on the label should also be legible.
- 12. The stereo printing of batch no., Mfg date, Exp date on the reverse side of strip/blister should run atleast two times.
- 13. The secondary packing (unit carton) should contain 10x10 or 20x10 capsules for item code 639, 640 and 641.
- 14. Quote rate in BOQ for the packing exactly given in annexure VIII. For example
 - If the packing unit is given for 10x10 tablets / capsule, the rate should be quoted for 10x10 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
 - If the packing unit is given for 10x10x1 tablets / capsule, the rate

- should be quoted for 10x10 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
- If the packing unit is given for 10x14 tablets / capsule, the rate should be quoted for 10x14 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
- If the packing unit is given for 2 ml ampoule (25 ampoules), the rate should be for 25 ampoules and not for 1 ampoule or 10 ampoules etc.
- If the packing unit is given for 2 ml ampoule (10 ampoules), the rate should be for 10 ampoules and not for 1 ampoule etc.

RAJASTHAN MEDICAL SERVICES CORPORATION

GUIDELINES FOR BLACKLISTING/DEBARRING OF PRODUCT OR SUPPLIER/COMPANY

1. ON SUBMISSION OF FALSE, FORGED OR FABRICATED DOCUMENTS OR CONCEALING OF FACTS:

The Bidder who submits false, forged or fabricated documents or conceals facts with intent to win over the Bid or procure purchase order; Bid Security Deposit of such Bidder firm will be forfeited and firm will be liable for blacklisting for a period of not Less than 2 years. The firm will also be liable for Legal action depending on the facts & circumstances of the case.

2. ON ACCOUNT OF FAILURE TO ENTER INTO AGREEMENT OR WITHDRAWL AFTER AGREEMENT OR REFUSAL / FAILURE TO SUPPLY:

- 2.1 The successful Bidder fails to execute the agreement after being declared as L-1, L-2 or L-3 etc. to perform the obligations under the Bid conditions, Bid Security Deposit of such Bidder firm will be forfeited and firm will be liable for blacklisting for a period of not less than 2 years or the period specified in Bid document.
- 2.2 The successful Bidder after entering into an agreement withdraw or fail to honour commitments as per Bid conditions, Performance Security of such Bidder firm will be forfeited and firm will be liable for blacklisting for a period of not Less than 2 years.

3. ON ACCOUNT OF NON-SUPPLY:

- 3.1 The supplier shall start to supply according to Bid condition from the date of purchase order and shall complete the supplies within 45/60 days as mentioned in Purchase Order or as stated in Bid condition.
- 3.2 RMSC will be at liberty to accept or reject the supply made belatedly as per the terms and conditions of the Bid documents. In the event of

- acceptance of delayed supply the liquidated damages shall be imposed at the rate stipulated in conditions of the Bid document.
- 3.3 If the supplier fails to execute the purchase order and informs RMSC about its inability to execute the order and non-compliance of the purchase order due to act of vis-majeure, then the Managing Director, RMSC will issue appropriate order on merits of case.
- 3.4 If the supplier fails to execute atleast 50% of the quantity mentioned in single purchase order and such failure in supply continues for three purchase orders, then supplier firm will be liable for blacklisting for a period of not Less than 2 years. As a result such supplier will be ineligible to participate in any of the Bids for particular item(s) of drugs / medicines for a period of not less than 2 years or the period specified in Bid document.

4. ON ACCOUNT OF QUALITY FAILURE OF DRUGS & MEDICINES:

- 4.1. The drugs supplied by the suppliers to the District Drug Warehouses are quarantined and samples of each and every batch of drugs /medicines are drawn on random basis and forwarded to Quality Control Wing of RMSC at the headquarter. The samples are then sorted; common batches pooled, coded and are sent to the empanelled laboratories for quality control test as per the QC Policy of RMSC.
- 4.2. Samples of all sterile surgicals & sutures items falling in the categories of drugs will also be drawn as per above policy and all of them will be subjected essentially for sterility testing.
- 4.3. If such samples pass quality test in all respects, RMSC will instruct its Warehouses to issue items of drugs to various hospitals / institutions
- 4.4. If the sample fails in quality test and report is received certifying that sample is not of standard quality, the drugs of the batch will not qualified for issue and supplier shall be informed to take back stocks of such batch, which failed the quality test and other consequences would follow as per the conditions in the Bid documents.

4.5. Minor Defects

- (1) If any batch of a particular item supplied under a tender tenure by the supplier is declared as Not of Standard Quality during its entire shelf life by an empanelled lab or Govt. Lab in test for assay and dissolution*/ or in any other parameter(s) and if such failure is further confirmed by another empanelled lab or Govt. Lab during its entire shelf life, the particular drug shall be liable for debarring for a period of not Less than one year.
- (2) If two or more batches of a supplier of a single drug or multiple drugs supplied under a tender tenure by the supplier is declared as Not of Standard Quality for minor defects, and such failure are further confirmed by another empanelled lab / Govt. Lab, then the product(s) of these batches shall be liable for debarring for a period of not less than two years.

 (*Tablets/Capsules failing in dissolution test and active contents found 70% and above for thermo labile products, and upto 5% less than the prescribed limits for thermo stable products.)

4.6. Grossly Substandard

- (1) If any batch of a particular item supplied under a tender tenure by the supplier is declared as Not of Standard Quality by an empanelled lab or Govt. Lab which falls in grossly substandard category and such failure is further confirmed by another empanelled lab / Govt. Lab, then the product shall be liable for debarring for a period of not Less than one (1) years.
- (2) If two or more batches supplied under a tender tenure by the supplier is declared as Not of Standard Quality by an empanelled lab or Govt. Lab, which falls in grossly substandard and such failure is further confirmed by Govt. Lab, then the Company shall be liable for debarring for a period of not less than two (2) years.
- 4.7. In case three products of a company/supplier are blacklisted for supply made during a Bid duration the Supplier / Company shall be liable for blacklisting for a period of not Less than 2 years.

4.8. Spurious or Adulterated

In case, any sample (even one batch) is declared as Not of Standard Quality by an empanelled lab or Govt. Lab which falls in Spurious or Adulterated category and if such failure is further confirmed by Govt. Lab during its entire shelf life, the Company shall be liable for debarring for a period of not less than 3 years.

if a company is debarred because of supply of Grossly Sub Standard and/or spurious/adulterated drugs, rate contracts with the delinquent company for other drugs will continue to be in force so far as these other drugs are found to be of 'Standard Quality'.

4.9. If any statutory sample of RMSC supply drug is drawn by Drugs Control Officer on suo-moto basis or on complaint and if it fails in quality parameters, the report is conclusive till it is challenged by supplier / company. If it is challenged then the report of Director, C.D.L., Kolkatta shall be conclusive and action as contemplated in foregoing paragraphs will be initiated in the matter of blacklisting of product or company. However if failure is of such nature wherein Drugs Controller of State grants prosecution sanction under Drugs & Cosmetics Act, 1940, then even failure of such one batch shall be considered adequate for blacklisting the product for not less than 2 years and in case of involvement of three different products the **Supplier / Company** as a whole shall be liable for blacklisting for a period of not Less than 3 years.

5. PROCEDURE IN THE EVENT OF QUALITY FAILURE WILL INVOLVE THE FOLLOWING STEPS:

- 5.1 On receipt of adverse quality test report from empanelled lab or Govt. Lab of a quarantined stock, instructions will be issued immediately through e-mail to the concerned District Drug Warehouses to not to release such stock and entries be made by QC Cell at headquarter in e-aushadhi software for batch rejection i.e. not to be released for distribution to institutions / DDC's.
- 5.2 Warehouse Incharge will take appropriate measures immediately to segregate such stock and label all cartons as "NOSQ Drugs-Not for release" and shift it from quarantine area to Non-Release / Rejected Drugs Area (which is under lock & key) till its lifting by the supplier.
- 5.3 Immediately on receipt of NOSQ report, the second sample should be sent to another empanelled lab / Govt. Lab by the QC Cell.
- 5.4 The supplier shall be informed immediately about the test results and instructions be issued to lift the entire stock at supplier's expenses of

such batch no. drug which is declared as "NOSQ" by the empanelled lab / Govt. Lab. However, in case of serious quality failure i.e. if drug is declared or adjudged spurious, adulterated or grossly substandard, one of drug warehouse incharge will be directed to contact the District Drugs Control officer for drawing statutory sample of such batch as per Act. The DDW Incharge has to keep adequate quantity of such drug for statutory sampling by Drugs Control officer.

- 5.5 In case of drug declared as **Not of Standard Quality** on subsequent sampling after the batch was released the procedure given in sub-para 5.2 will be followed in respect of stock available with the warehouse. In respect of stock already issued and drug warehouse in charge will take immediate steps to RETRIEVE the unused stock of such drugs from all such institutions and D.D.C.s by all possible mode and means and he/she will ensure that no such NOSQ drug is further distributed to the patients and ensure effective recall.
- On receipt of test report from empanelled lab / Govt. Lab, show cause notice will be issued immediately to the concerned supplier calling for explanation within 3 days from the date of receipt of notice in respect of quality failure of concerned batches of drug. The supplier will be required to submit the batch manufacturing record, batch analysis report, raw material purchase record & raw material test reports etc. Opportunity for personal hearing, if desired by supplier, may also be accorded.
- 5.7 On confirmation of the test result by the second laboratory, the case will be referred to the disciplinary committee of RMSC for further action.
- 5.8 In case when the second report is contradictory to the first report, the statutory sample will be sent to Govt. Lab, whose report will be final and if the sample has been tested by the Govt. Lab at any stage, its report will be conclusive & final unless challenged as per provisions of Drugs & Cosmetics Act, 1940.

6. EXAMINATIONS OF ISSUES BY DISCIPLINARY COMMITTEE OF RMSC

- 6.1. Each & every case of submission of false documents, failure to execute agreement, non-supply or quality failure, etc. will be referred to disciplinary committee of RMSC for examination on a case to case basis for making appropriate technical recommendation to Managing Director for further appropriate action.
- 6.2. The recommendations of disciplinary committee will be placed before the Managing Director, RMSC who shall take appropriate action which may deem fit in the light of facts & circumstances of the case by way imposing penalty or debarring or Blacklisting of the particular product or supplier/company.
- 6.3. If, the quality failure is of such nature that a particular product has been blacklisted according to the procedure stated above, the supplier will not be eligible for participating in any of the Bids for the particular item floated by RMSC for the specified period. For such purpose period of blacklisting will be counted from date of issue of order and it will deemed to be over on completion of the period and as such no fresh orders will normally be required for re-eligibility purpose. Similarly if the supplier /company is blacklisted the supplier will not be eligible for participating in any of the Bids for any of the items during blacklisted period.

7. POWER OF REVIEW:

Subsequent to the action taken on the basis of available facts if some new facts & evidences such as reversal of test results findings by Appellate Laboratories etc. are brought to the notice of the corporation, the Managing Director of RMSC will have the right to review the earlier action. He may seek advice from the disciplinary committee in such matters.

8. RIGHT TO APPEAL:

Any supplier / company against whom the above action is taken may prefer an appeal within 30 days of date of blacklisting order to the Principal Health Secretary, Medical & Health Department, Govt. of Rajasthan who shall decide the same.

9. Savings:

The blacklisting of particular product or supplier / firm will be done without prejudice to other penalty which may be imposed as per the conditions of Bid documents and also to other actions which may be initiated under Drugs and Cosmetics Act 1940 or any other law of land. RMSC will display names of such blacklisted products and companies on its website and also circulate the same among all stakeholders viz. PSME, DM&HS, DC including respective State Drug Controllers where the supplier / company is located.

10. JURISDICTION:

In the event of any dispute arising out of the orders and implementation thereof, such dispute shall be subject to the jurisdiction of the Courts of Jaipur City only or Hon'ble Rajasthan High Court, Bench at Jaipur.

EXPLANATIONS:

- (i) Increase in the cost of raw materials, power cut, Labour strike, insolvency, closure of the factory would not be considered as act of vismajeure.
- (ii) For the drugs failing in Quantative analysis (Assay), following treatment is to be given:-

On the basis of quantitative analysis (Assay), the NOSQ drug shall be distinguished in the following manner:-

| Category of NOSQ drugs | Active ingredient content (Assay) | | | | |
|------------------------|---|---|--|--|--|
| | Thermo stable | Thermolabile | | | |
| Minor | Upto 5% less than the prescribed lower limit | Above 70% to the prescribed lower limit | | | |
| Grossly Substandard | Below 5% of the prescribed lower limit to 50% | 70% to 40% | | | |
| Spurious | Below 50% | Below 40% | | | |

- (iii) Purchase Orders, if any, already issued before taking any blacklisting action or replacement orders given in past will not be affected in view of action taken as per above guidelines
- (iv) The action proposed as above is not in conflict to any express conditions laid down in corresponding Bid and in case of any overlapping, the Bid condition will prevail.

ANNEXURE-X FORM NO. 1 [See rule 83 of RTPP]

Memorandum of Appeal under the Rajasthan Transparency in Public Procurement Act, 2012

| Appeal No |
|--|
| Particulars of appellant: (i) Name of the appellant: (ii) Official Address, if any: (iii) Residential address: |
| Name and address of the respondent (S):(i)(ii)(iii) |
| 3. Number and date of the order appealed against and name and designation of the officer/ authority who passed the order (enclose copy), or a statement of a decision, action or omission of the Procuring Entity in contravention to the provisions of the Act by which the appellant is aggrieved: |
| 4. If the Appellant proposes to be represented by a representative, the name and postal address of the representative: |
| 5. Number of affidavits and documents enclosed with the appeal: |
| 6. Ground of appeal: |
| |
| |
| 7. Prayer: |
| |
| Place Date |
| Appellant's Signature |

UNDERTAKING FOR EMPANELMENT

| I | Name | S/o | | Age | Prop./Partne | r/Director/ |
|-------|------------------|----------------|-----------|------------|--------------|-------------|
| Powe | er of attorney l | holder of firm | M/s | | situated at | (Complete |
| addre | ess of Mfg. uni | it) | bearing | drug licen | se on Form 2 | 25 & 28 or |
| form | 10 bearing | Number | 8 | | re | spectively, |
| issue | d on dated | va | lid/Renew | ed up to | | do here |
| by de | eclare on oath a | s follows:- | | | | |

- That I have applied for empanelment for supply of Drugs & Medicines for the items I have quoted in the bid as enlisted in Annexure –VII
- 2. That I/We have carefully read all the conditions of Bid in Ref. no. F.02(169)/RMSC/PROCUREMENT/DRUG/NIB-01/2015/01 Dated:01.01.2016 for supply Cum rate contract and empanelment for supply of Drug and Medicines For Rajasthan Medical Services Corporation and accept all conditions of Bid, including amendments if any.
- 3. That I will be considered empanelled for the items which are declared technically responsive.
- 4. That I have deposited the required fees for empanelment or previous bid ref no......

Date

Name & Signature with Seal

Annexure-XII Ref. Clause No.17.2

Supplier Consolidated Invoice

| Name of Supplier: Complete Address: E-mail ID: | | | | | | | | | | | |
|---|----------|-----------|-----------------------|-------|----------|----------------------|--------|--------------|-------------------|-------------------|-----------------------|
| DL NO.: TIN No | | | | | TIN No | .: | | | Invoice N | lo.: | |
| | | | | | | | | Date: | | | |
| Purchaser: Managing Director Address: Rajasthan Medical Services Corpor | | | | | .• | | | der No.: | | | |
| | | | Aedical S naya Bha | | | | Date: | | | | |
| | | | No. 014 | | | ig, C- | | | | | |
| Schen | ic, suip | ar r none | 7110.011 | 1 222 | 0000 | | | | | | |
| RMSC | C TIN N | O.0840 | 4750762 | | | | | | | | |
| Name | of Iten | n/Descri | ption : | ••••• | •••• | Drug C | ode (R | MSC) | : | ••••• | ••• |
| S.No | Name | Odered | Invoice/ | Date | Packing | Batch | Mfg. | Eve | Quantity | Basic Rate | Basic |
| 3.110 | of | Qty. | Challan | Date | Size | No. | Date | Exp. Date | Supplied | (without | Amount |
| | DDW | | no. | | | | | | in No. (Batch | Concessional CST) | (without Concessio |
| | | | | | | | | | wise) | CS1) | nal CST) |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| D - 1 | 1 | | | | | T-(1 D | _: _ A | | | | |
| Remar | KS: | | | | | Total Ba | | | nal CST acc | ninst C-form & | |
| | | | | | Total Ta | | | iai Co i aga | 11115t C-101111 & | | |
| | | | | | | TOTAL INVOICE AMOUNT | | | | | |

Authorised Signatory

Annexure-XIII
Ref. Clause No. 17.2

Analytical Report Regarding Quality

| Nam | e of Supplier:- | | | | | |
|-----------|----------------------|--------------------|------|-----------|------------------|--------|
| Addı | ress:- | | | | | |
| PO N | No:- | Date:- | | | | |
| Drug | g Name:- | | | | | |
| Deta | ils of in house test | report:- | | | | |
| S. No. | Name of Lab. | Test report No. | Date | Batch No. | Qty. Supplied | Result |
| 1. | | | | | | |
| 2. | | | | | | |
| 3. | | | | | | |
| 4. | | | | | | |
| 5. | | | | | | |
| 6. | | | | | | |
| 7. | | | | | | |
| 8. | | | | | | |
| 9. | | | | | | |
| 10. | | | | | | |
| 11. | | | | | | |
| 12. | | | | | | |

Authorised Signatory

Security form (Bank guarantee)

| To, |
|---|
| Managing Director Rajasthan Medical Services Corporation Ltd WHEREAS(Name of Supplier) |
| Hereinafter called "the Supplier" has undertaken, in pursuance of Contract (Letter of Acceptance) No. dated 2016 to supply. (Description of Goods) hereinafter called "the Contract". |
| AND WHEREAS it has been stipulated by you in the said Contract that the Supplier shall furnish you a bank Guarantee from a Scheduled Bank for the sum specified therein as security for compliance with the Supplier's performance obligations in accordance with the Contract. AND WHEREAS we have agreed to give the supplier a Guarantee: |
| THEREFORE WE hereby affirm that we are Guarantors and responsible to you, on behalf of the Supplier, up to a total of |
| in Words and Figures) and we undertake to pay you, upon your first written demand declaring the Supplier to be in default under the said Contract and/or any other contract or for set off any other dues pending against the supplier, without cavil or argument, any sum or sums within the limit of(Amount of Guarantee) as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein. |
| This Bank guarantee is payable at Jaipur Branch |
| This guarantee is valid until the day of 2019 |
| Signatures and Seal of Guarantors |
| Date |
| Address: |
| |

Note:- The validity of bank guarantee should be for 36 months from the date of issuance of Bank Guarantee.

PERFORMANCE STATEMENT

(The statement may be given for year 2011-12, 2012-13, 2013-14 or 2012-13, 2013-14, 2014-15 or 2013-14, 2014-15, 2015-16)

Name of Firm:

| S. | Item | Name | Financial Year | | Financial Year | | Financial Year | |
|-----|------|------|--------------------------------|---------------------------------------|-----------------------------|---------------------------------------|-----------------------------|---------------------------------------|
| No. | Code | of | | | | | | |
| | no. | Item | | | | | | |
| | | | No. of Batches manufactured | No. of Batches declared NOSQ | No. of Batches manufactured | No. of Batches declared NOSQ | No. of Batches manufactured | No. of Batches declared NOSQ |
| | | | | | | | | |

The information as given above is true and correct. If any information furnished by me as above is found wrong; I shall be solely responsible and suitable action may be taken against my firm.

Signature & Seal of the Bidder